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ABSTRACT 
 
In sub-Saharan Africa a causal relationship has been established between hepatitis B 
virus (HBV) infection and membranous nephropathy (MN), especially in Black children. 
The most common method of treatment is interferon therapy, which is however, only 
effective in 30-40% of patients. The reason for this is unclear. The objective of this pilot 
study was to determine whether mutations in the complete surface gene of HBV isolated 
from Black children with HBV-associated MN before, during and after treatment with 
interferon, had any effect on treatment response and vice versa. HBV DNA was extracted 
from the serum of a responder, reverter and non-responder patient before, during (4 and 
16 weeks) and after (40 weeks) IFN treatment. The preS1/preS2/S region was amplified 
and cloned, and the clones sequenced. Sequence analyses revealed the preS2 region to be 
the most variable in the reverter and non-responder and HBsAg was the most variable in 
the non-responder. Phylogenetic analysis showed that the viral population dynamics 
between the responder strains and the reverter/non-responder strains differed as a result 
of various mutations found within the surface gene. Thus the presence of mutations in 
preS2 and HBsAg of the non-responding patients may carry predictive markers for non-
response but further investigation would be needed to conclusively prove this.  
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Chapter 1: INTRODUCTION 
 
Hepatitis B virus (HBV) is an important cause of chronic hepatitis, cirrhosis and 
hepatocellular carcinoma. In addition, a causal relationship has been established between 
HBV and membranous nephropathy (MN), a kidney disorder that may occur, especially 
in children (Bhimma et al., 1998). With an estimated 385 million carriers of HBV world-
wide, and a mortality rate of 1.2 million deaths per year as a result of acute or chronic 
HBV infection (King et al., 2002), HBV remains a major public health problem. In 
Africa, with a population of approximately 470 million people and where HBV is 
hyperendemic, as many as 98% of the population are infected with HBV at some point in 
their lives (Kew, 1996). Equally impressive, is the fact that more than 230 000 Africans 
will die each year from HBV-induced diseases (Kew, 1992).  
 
Even though an effective and safe vaccine for the prevention of HBV infection exists, the 
treatment of those already living with chronic HBV infection is unsatisfactory. 
Interferon-alpha (IFNα) was the first approved agent for the treatment of chronic HBV 
infection (Lai et al., 2002a). Its efficacy is however, limited. In a previous study, IFNα 
was used to treat nineteen Black children with HBV-associated membranous 
nephropathy.  At 40 weeks of follow-up, ten patients (52.6%) had cleared HBeAg 
(responders), four (21.1%) had cleared HBeAg during treatment but then reverted to 
being HBeAg-positive (reverters), and five patients (31.6%) failed to clear HBeAg (non-
responders). None cleared HBsAg. The aim of the present study was to determine 
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whether differences in the genomic structure of HBV isolates from IFNα treated patients 
could account for the variation in response to treatment.   
 
1.1 HEPATITIS B VIRUS 
1.1.1 Classification 
 
HBV belongs to the family of enveloped DNA viruses, the Hepadnaviridae, which share 
a similar structural and genomic organization (Scaglioni et al., 1996). The members of 
this family that infect mammals are grouped in the genus Orthohepadnavirus, whereas 
those that infect birds belong to the genus Avihepadnavirus (Seeger and Mason, 2000).  
All hepadnaviruses contain a partially double-stranded DNA genome, but replicate via an 
RNA intermediate, the pregenome, which encodes an error-prone polymerase enzyme 
with both DNA polymerase and reverse transcriptase activity (MacDonald et al., 2000).   
 
Hepadnaviruses have a narrow host range, with HBV being able to infect humans and 
chimpanzees only (Lai, 2002b). The primary target of infection with HBV and other 
human hepatitis viruses is the liver, with transmission being via the parenteral route.  
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1.1.2 Epidemiology 
 
HBV infection occurs throughout the world but in widely differing frequencies. 
Socioeconomic factors, the proportion of the population with risky lifestyles, the current 
prevalence of HBV, the availability of vaccination programs and compliance to hygienic 
measures, all contribute to a country’s epidemiological status (Grob, 1995). The most 
common routes of HBV transmission include needle sticks (accidental injuries and drug 
use), sexual contact, blood transfusions and mothers to newborns (Grob, 1995).  
 
The world can generally be divided into low (<2%), intermediate (2-8%) and high (>8) 
endemicity areas (Figure 1.1) (McMahon, 2005), but this is changing over time following 
the introduction of vaccination programs. There may also be substantial epidemiological 
differences between countries in the same continent. In general, HBV is highly endemic 
in developing countries with large populations and most infections in highly endemic 
areas occur during infancy or early childhood (Hou et al., 2005). Most of Asia, the South 
Pacific Island region and the Arctic/sub-Arctic are high endemicity areas (Hou et al., 
2005; McMahon, 2005). Amongst the South-East Asian areas, China, Taiwan, Korea and 
Thailand are classified as high endemicity areas, with a 7-20% prevalence of hepatitis B 
surface antigen (HBsAg) (André, 2000). HBV is highly endemic in most of West, East, 
Central and sub-Saharan Africa with chronic infection rates of 7-26%, although areas like 
Tunisia, Morocco and Zambia fall into the intermediate category (André, 2000). Egypt, 
Jordan, Oman, Palestine, Yemen and Saudi Arabia are also high endemicity areas (André, 
2000).  
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 In areas of moderate endemicity, transmission is usually mixed and includes infant, early 
childhood and adult transmission (Hou et al., 2005). The Mediterranean, Southern and 
Eastern Europe, North Africa, the Middle East, India and parts of South America fall into 
the intermediate endemicity category (McMahon, 2005) as do Cyprus, Iraq, India, the 
Philippines and the United Arab Emirates (André, 2000).  
 
 
 
 
Figure 1.1: Worldwide distribution of chronic HBV infection showing the high, intermediate and low 
prevalence areas (www.safetyline.wa.gov.au/institute/level2/course20/lecture81/l81_02.asp). 
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Most areas in the Middle East, Bahrain, Iran, Israel and Kuwait are low endemic areas 
because of mass vaccination programs, which have begun to control the spread of HBV 
by decreasing HBsAg carrier rates to under 2% (André, 2000). In developed areas such as 
the United States of America and Northern and Western Europe, HBV infection rates are 
low (Hou et al., 2005), whilst Japan, Pakistan, Bangladesh and Sri Lanka are also seen as 
low endemic areas with a HBsAg prevalence of 0.2-1.9% (André, 2000). Transmission of 
HBV infection in low endemic areas are generally as a result of well-defined high risk 
groups such as drug-users, homosexuals, blood transfusion patients and health care 
workers (Hou et al., 2005)  
 
1.1.3 Transmission  
 
HBV can be transmitted horizontally by blood, blood products and body fluids such as 
saliva, sweat, semen, breast milk, urine and faeces (Prescott et al., 1999), with blood 
products and semen carrying a greater risk than other bodily fluids. Chronic HBV 
infection is very common in sub-Saharan Africa where the high carrier rate of the virus is 
largely established in early childhood (1-5 years of age), mainly by horizontal 
transmission of the virus via contact with siblings and unrelated playmates as well as 
other family members (Kew, 1996). These are the most common routes of transmission 
amongst children of this age (Tsebe et al., 2001). Bites from mosquitoes and bed bugs, as 
well as scarification of the skin by witch doctors, might play a lesser role in the 
horizontal spread of HBV in sub-Saharan Africa (Kew, 1996).  
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HBV infected mothers may also pass the virus from their blood onto the fetus, through 
the placenta, more commonly termed vertical transmission. It has been shown that infants 
have a greater than 90% chance of becoming HBV carriers if their mothers are hepatitis 
B e antigen (HBeAg) positive (Hino et al., 2001). Vertical transmission however, even 
from highly infectious mothers, appears to be rare in Africa.  When a HBV carrier mother 
infects the child during or shortly after delivery, it is termed peri-natal transmission. 
Transmission via this route is uncommon in Africa but occurs frequently in China and the 
Far East.  
 
1.1.4 Biology 
 
The HBV virion or Dane particle is made up of an outer shell, consisting of envelope 
proteins and a small amount of lipid, and an inner nucleocapsid (Scaglioni et al., 1996; 
Seeger and Mason, 2000). The virion has a diameter of 27 – 42nm. Within the lumen of 
the nucleocapsid (core), is contained the partially double-stranded relaxed circular DNA 
(rcDNA), covalently bound to the viral polymerase (Figure 1.2) (Kann, 2002).  The 
negative strand of the HBV genome is approximately 3.2 kb in length and consists of four 
open reading frames encoding viral proteins and cis-acting elements needed for 
regulating HBV gene expression and replication (Arbuthnot et al., 2000). The circular 
structure of the genome is maintained by the positive strand of variable length which 
cohesively binds to the 5’ and 3’ ends of the negative strand (Arbuthnot et al., 2000). 
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Figure 1.2: The morphology of a hepatitis B virion demonstrating the double layered shell consisting 
of the small, middle and large glycosylated surface proteins as well as the lipid bilayer; the core made up of 
core proteins; the polymerase protein; the enzymatic proteins and the partially double stranded DNA 
genome. Heat shock proteins are found within the envelope shell (Kann, 2002).  
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Besides HBV virions, the serum of infected individuals also contains an excess of   
subviral particles: spherical ~22nm particles and filamentous particles that vary in length 
(Figure 1.3) (Prescott et al., 1999). These spheres and filamentous particles consist of 
viral surface proteins and host-derived lipid components (Kann, 2002) only, and unlike 
the Dane particle, are non-infectious (Prescott et al., 1999).  During infection, circulating 
viral particles may have a concentration ranging from 103 to 109 viral particles per 
millimeter of serum, whilst subviral particles may range anywhere from between 106 and 
1014 particles per millimeter (Scaglioni et al., 1996). Although these subviral particles 
lack DNA or RNA and are therefore not infectious, they are nevertheless highly 
immunogenic. 
 
 
Filamentous form                                    Dane particle                   Spherical particle  
Figure 1.3: An electron micrograph (x210,000) of hepatitis B virus in serum showing the three 
distinct subviral particles; the spherical and filamentous particles consisting of only viral surface proteins 
and host-derived lipid components and the complete infectious virion or Dane particle (Prescott et al., 
1999). 
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1.1.5 Lifecycle 
1.1.5.1 Entry into Hepatocytes 
 
Entry of the virus into the host cells is mediated by the initial attachment of HBV to an as 
yet unidentified receptor, followed by receptor-mediated endocytosis into the hepatocytes 
(Figure 1.5) (Scaglioni et al., 1996). Once inside the host cell, the viral envelope is 
removed by host factors and the core protein conveys the viral genome to the nucleus via 
a nuclear localization signal contained within the nucleocapsid (Yeh et al., 1990; 
Scaglioni et al., 1996).  Before entering the nucleus, the nucleocapsid is disassembled on 
the cytoplasmic side of the nuclear membrane, thus allowing the viral DNA to enter the 
nucleus and initiate replication (Scaglioni et al., 1996).    
 
1.1.5.2 Formation of Covalently Closed Circular DNA (cccDNA) 
 
The first step in HBV replication is the conversion of the HBV genome from rcDNA to a 
double-stranded covalently closed circular DNA (cccDNA) (Figure 1.5). The cccDNA 
acts as the template for synthesis of all viral transcripts involved in protein production 
and replication (Doo and Liang, 2001; Arbuthnot et al., 2000). A 3.5 kb mRNA or 
pregenomic RNA (pgRNA) encodes the core and polymerase proteins, the 2.4 kb and 2.1 
kb transcripts encode the surface envelope proteins, whilst a 0.7 kb transcript encodes the 
X-protein (Figure 1.4) (Doo and Liang, 2001; Ganem and Schneider, 2001). 
Transcription of these four proteins is initiated by different gene promoters; the enhancer 
II/basal core, large surface antigen, major surface antigen and enhancer I/X, respectively. 
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Transcripts terminate at a single polyadenylation site on the cccDNA (Arbuthnot et al., 
2000; Ganem and Schneider, 2001).  The pgRNA is longer than the full genome length of 
HBV and the 5’ and 3’ ends contain a terminal redundancy region, which act as the cis-
acting motifs, namely DR1, a direct repeat of 12 nucleotides, and epsilon (ε), a secondary 
stem-loop structure (Scaglioni et al., 1996).  
 
 
 
 
Figure 1.4: The circular structure of the HBV genome showing the plus (+) and minus (-) sense 
strands. The arrow bars indicate the four overlapping open reading frames of HBV and their corresponding 
protein products. DR1 and DR2 are also illustrated on the 5’ and 3’ ends (Kann, 2002). 
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For reverse transcription and encapsidation of the pgRNA to occur, the viral polymerase 
has to bind to the 5’ ε on its own RNA template, via 3 host chaperone proteins. p23 and 
heat shock protein 70 (Hsp70) aid the binding of the polymerase to ε, whilst Hsp60 is 
involved in the activation of the viral polymerase (Park and Jung, 2001).  This interaction 
further leads to complex formation with the core proteins, to form nucleocapsids (Doo 
and Liang, 2001). A second function of this interaction is the initiation of reverse 
transcription of the pgRNA to yield a negative DNA strand. This only occurs when 
polymerase binds to ε and acts as a primer to initiate the reverse transcription of a 3 
nucleotide long oligonucleotide that will covalently link to the polymerase (Scaglioni et 
al., 1996; Doo and Liang, 2001). Translocation and annealing of the polymerase-primer 
complex to the complementary 3’ DR1 end sequence of the pgRNA, leads to the 
synthesis of a negative stranded DNA.  
 
DNA strand synthesis occurs within the nucleocapsid, whilst the polymerase derived 
ribonuclease (RNase) H activity degrades all but the last 15-18 nucleotides at the 5’ end 
of the pgRNA (Scaglioni et al., 1996; Doo and Liang, 2001). It is this undegraded RNA 
molecule that serves as the template for positive DNA strand synthesis when it transfers 
to DR2, the direct repeat complementary to DR1 but located downstream from the 5’ end 
copy on the negative DNA strand. Circularization of the HBV genome occurs once 
positive strand synthesis has extended to the end of the negative strand. Binding of the 
core to the N-terminal domains of the envelope proteins, leads to the translocation of the 
core across the endoplasmic reticular membrane, into the Golgi complex, and ends with 
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the secretion of mature virions into the bloodstream (Figure 1.5) (Seeger and Mason, 
2000).  
 
 
 
Figure 1.5: Binding of HBV to the surface of the hepatocyte via the envelope proteins, leads to entry 
into the cell by endocytosis. Once inside, the virus is transported to the nucleus where the HBV genome is 
converted from rcDNA to cccDNA. Transcription of mRNA and the pgRNA occurs using the cccDNA as 
the template. The RNAs move to the cytoplasm where they are translated to produce viral proteins. Binding 
of the core to all three envelope proteins leads to the translocation of the virus across the endoplasmic 
reticulum and ends with the secretion of mature virions into the bloodstream.   
(www.prn.org/prn_nb_cntnt/vol6/num1/img_pgs/locarnini.fig1.htm) 
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1.1.6 Gene expression 
1.1.6.1 Precore/Core ORF 
 
The precore/core open reading frame (ORF) contains two start codons coding for two 
overlapping proteins (Ganem, 1991). If translation begins at the second AUG start codon, 
a 21.5 kDa core protein is synthesized, which can be either 183, 185 or 195 amino acids 
in length depending on viral genotype (Kann, 2002; Locarnini et al., 2003). The core 
protein assembles into the nucleocapsid or viral capsid, and is known as the hepatitis B 
virus core antigen (HBcAg) (Seeger and Mason, 2000).  Two distinct functional domains 
within the core protein can be distinguished. Amino acids 1-144 of the core protein are 
needed for assembly of the nucleocapsid, while amino acids 150-164 at the arginine-rich 
C-terminal end of the protein mediate nucleic acid binding, encapsidation of the pgRNA 
and stabilization of the capsid protein (Kreutz, 2002; Locarnini et al., 2003). The 
remaining amino acids, 165-173, may be involved in DNA replication. Assembly of core 
particles is mediated via the dimerization of the first 147 amino acids, resulting in the 
formation of subviral core particles held together by disulphide bonds (Seeger and 
Mason, 2000; Kann, 2002). The dimerized particles then assemble into an icosahedral 
shell consisting of T3 (180 core proteins) or T4 (240 core proteins) symmetries and a 
diameter of 32 or 36nm (Seeger and Mason, 2000). One hundred and twenty 2nm spikes 
can be visualized on the surface of the icosahedrons and represent immunodominant 
regions. 
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Translation from the first AUG, or precore start codon, will generate a precore/core 
precursor protein. The first 19 amino acids of the precore protein form a signal which 
mediates the translocation of the protein to the endoplasmic reticulum (ER). Once there, 
the 19 amino acids are cleaved off by a host cell signal peptidase and a variable number 
of amino acids are cleaved off from the C-terminal end (Ganem and Schneider, 2001; 
Locarnini et al., 2003).  The resulting protein is correctly folded in the ER. It is 15-18 
kDa in size and termed the HBeAg. HBeAg is secreted via the Golgi apparatus and is 
also expressed on the surface of hepatocytes. The HBe protein is involved in the 
establishment of persistent infection (Locarnini et al., 2003) and may also function as an 
immunoregulator by behaving as a tolerogen in order to inactivate specific T-cell activity 
and promote chronicity (Chen et al., 2005).   
 
1.1.6.2 Polymerase ORF 
 
The second translation product from the pgRNA is the viral polymerase. The polymerase 
ORF is the longest and encodes the multifunctional 90 kDa enzyme via an internal 
initiator codon on the pgRNA (Seeger and Mason, 2000). The multifunctional nature of 
the 845 amino acid viral polymerase is as a result of the distinct domains on the protein, 
(Doo and Liang, 2001; Kann, 2002).  The N-terminal domain codes for the terminal 
protein (TP), which is involved in minus-strand DNA synthesis and is followed by a 
spacer region with no specific function (Kreutz, 2002; Locarnini et al., 2003). A third 
domain codes for the recognition site of the enzyme and is termed the catalytic domain, 
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while a fourth domain at the C-terminal end encodes RNase H activity (Kreutz, 2002; 
Locarnini et al., 2003).    
 
1.1.6.3 X ORF 
 
The X ORF is highly conserved and encodes a 154 amino acid, 17 kDa protein termed 
HBx (Locarnini et al., 2003).  HBx is divided into 6 domains, A-F, the C-terminus of the 
protein being the transactivating portion, whilst the N-terminal region is involved in 
repression of HBx transactivation, thereby having a self-regulatory role (Kreutz, 2002).  
 
HBx is believed to be a transcriptional activator, implicated in hepatocarcinogenesis 
(HCC) by inhibiting the tumor suppressor protein p53, apoptosis and the repair of 
damaged hepatocyte DNA (Arbuthnot et al., 2000). It also plays an essential, albeit 
poorly understood role, in the establishment of HBV infection (Kann, 2002).  
 
1.1.6.4 Envelope ORF 
 
Three distinct surface/envelope proteins, large (L), medium (M) and small (S), are 
produced by HBV to form the envelope of the virus and can be distinguished by three 
domains (Heerman et al., 1984) (Table 1.1). 
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Table 1.1: The 3 domains of the envelope/surface proteins 
 Surface proteins Domains 
Large PreS1, PreS2 and S 
Medium PreS2 and S 
Small S 
 
  
 
 
 
All three polypeptides are encoded by the same ORF via three in-frame translation 
initiation codons (AUG’s) and a common stop codon (Gerner et al., 1998). As a result of 
this, all three proteins share the same carboxy-terminus but differ at their amino-terminal 
ends (Chang et al., 2004; Raimondo et al., 2004). All three of the envelope proteins are 
glycosylated to different extents, are type II transmembrane proteins, and are stabilized 
by disulphide bridges formed by cysteine residues (Seeger and Mason, 2000). The preS1 
and S proteins are essential for the viral life cycle, but preS2 appears to be dispensable 
for virion formation, secretion and infectivity (Raimondo et al., 2004). 
 
Synthesis of the envelope proteins is regulated by two separate promoters; the preS1-
promoter is responsible for transcription of mRNA to be translated into the preS1 or large 
surface antigen, and the S-promoter that is responsible for transcripts with different 5’ 
ends, which are then translated into the preS2 or middle and S antigen or small protein 
(Chang et al., 2004).   
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1.1.6.4.1 Small Envelope Protein 
 
Also referred to as HBsAg, this protein is composed of 226 amino acids and is the most 
abundantly found of all three envelope proteins (Figure 1.6a) (Khan et al., 2004).  
 
50%-60% of the small envelope protein is folded into α-helices numbered I – V, by 4-5 
lengths of hydrophobic amino acids (Figure 1.6a) (Kann, 2002). Amino acids 11-29 of 
helix I, crosses the ER membrane and translocates the upstream sequence into the ER 
lumen (Kann, 2002). In infected hepatocytes, HBsAg can be found buried in the 
endoplasmic reticulum membrane, with residues 29-79 forming the major cytoplasmic 
loop (Khan et al., 2004). The region between helix I and II, corresponding to amino acids 
80-98, is found in the cytoplasm and therefore has no epitopes (Kann, 2002). Residues 
101–168 of helix II, is termed the immunodominant region. This region contains a high 
number of cysteine residues, which are cross-linked with each other to form a loop 
configuration, the major antigenic determinant of HBsAg, known as the ‘a’ determinant 
(Locarnini et al., 2003). The ‘a’ determinant is common for all four serological subtypes 
and is defined by a threonine or isoleucine at position 126 of HBsAg (Kramvis et al., 
2005). Amino acid substitutions at positions 122 and 160 of HBsAg are used to 
distinguish between serotypes d/y and w/r (Okamoto et al., 1987a).  The ‘a’ determinant 
(amino acids 124-147) is clinically the most important because during infection 
antibodies against all determinants will be produced, but it is only those against the ‘a’ 
determinant that will protect against other HBV serological subtypes (Kreutz, 2002).  
Because of the abundance of cysteine residues in the immunodominant loop, this region 
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may also be involved in the formation of intramolecular and intermolecular disulphide 
bonds, which may lead to the important event of oligomerization of HBsAg and thus its 
secretion (Khan et al., 2004). Downstream of helix II is helix III, passing through the ER, 
with helices IV and V spanning the ER membrane (Kann, 2002).  
 
1.1.6.4.2 Medium Envelope Protein 
 
The medium envelope protein, or preS2, is composed of the S domain in addition to 55 
amino acids on its N-terminus (Figure 1.6b) (Locarnini et al., 2003; Chang et al., 2004).  
PreS2 is N-glycosylated with a glycan at amino acid 4 and may additionally have an O-
glycan at position 37 in HBV genotypes B-F (Kann, 2002). 90% of preS2 molecules are 
further modified by the acetylation of their N-terminal methionines (Kann, 2002).  
 
The role of the preS2 protein is not well defined, but seems to be unnecessary for virion 
assembly, secretion and infectivity as demonstrated by in vitro and in vivo studies 
(Gerner et al., 1998; Raimondo et al., 2004). Because of this, the emergence of preS2-
defective mutants has become apparent in HBV infected individuals. PreS2 variants can 
be grouped into two distinct types (Raimondo et al., 2004): 
• Variants unable to synthesize the M protein because of mutations at the level of 
the preS2 start codon, 
• Variants that produce shortened M surface proteins because of in-frame deletions.  
As preS2 has been shown to bind specifically to fibronectin found in human liver 
sinusoids, Kreutz et al (2002) proposed that, contrary to other studies, it may be involved 
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in viral attachment to host tissues. Amino acids 3-16 have also been shown to contain a 
binding site for human serum albumin, thus further hinting to a role in the enhancement 
of virus and target cell binding (Kann, 2002).  
 
1.1.6.4.3 Large Envelope Protein 
 
The preS1 domain is made up of the entire S and preS2 domains, in addition to an extra 
108-119 amino acids on its N-terminus, depending on subtype/genotype (Raimondo et 
al., 2004). The large envelope protein may have different topologies; it can either be 
located in the ER and therefore exposed to the surface (Figure 1.6c), or it can be located 
in the cytosol and thus localized in the lumen (Figure 1.6d) (Kann, 2002). On account of 
this, preS1 may have two separate roles.  
 
The large envelope protein contains two important epitopes. One is believed to be 
recognized by antibodies involved in viral clearance, and the other may be a hepatocyte 
binding region (Kreutz, 2002). It has since been shown by Glebe et al (2005), that preS1 
is acylated by a myristic acid at glycine 2, which allows for efficient infectivity of the 
virus to its target cell, and that sequence 2-48 of preS1 mediates this attachment. This is 
in accordance with a previous study in which myristylation was found to be conserved 
among all hepadnaviruses, thus suggesting an important role in the viral lifecycle 
(Grippon, 1995).  
PreS1 therefore seems to be essential for attachment of the virus to its target cell. The 
moderate hydrophobicity of the N-terminal myristoyl acid promotes protein to membrane 
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interactions that, during the interaction of the preS1 and its receptor, inserts into the 
membrane and thus strongly enhances this interaction, leading to nucleocapsid entry into 
the cytoplasm (Glebe et al., 2005). The preS1 also has antigenic sites for B and T cells 
involved in recovery and protection from viral infection (Locarnini et al., 2003).  When 
preS1 anchors itself to the ER membrane, it exposes itself in its entirety to the cytosol, 
and residues 103-124 have thus been implicated in HBV envelopment and secretion 
(Khan et al., 2004). 
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Figure 1.6: Topologies of the 3 surface proteins. (a) Small surface protein (b) middle surface protein. 
The top of each picture represents the lumen of the ER/preGolgi compartment, whilst the bottom 
corresponds to the cytosol or interior of the virus. The α-helices are numbered I-V. N- or O- 
glycosylations are marked N- or O-glyc (Kann, 2002). 
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Figure 1.6: Topologies of the 3 surface proteins. (c) Large surface protein with ER localized preS (d) 
large surface protein with cytoplasmically localized preS.  The top of each picture represents the lumen of 
the ER/preGolgi compartment, whilst the bottom corresponds to the cytosol or interior of the virus. The α-
helices are numbered I-V. N- or O- glycosylations are marked N- or O-glyc (Kann, 2002).  
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1.1.7 HBV Genotypes 
 
A viral genotype refers to the form in which the genomic sequence of a virus that is 
replication competent has stabilized after a prolonged period of time (Francois et al., 
2001, Kramvis et al., 2005). HBV polymerase lacks proof-reading activity and the 
genome may evolve at an estimated error rate of 1.4 - 5 x 10-5 nucleotide 
substitutions/site/year (Okamoto et al., 1987b). As a result of this evolution, genotypes 
and subgenotypes of HBV have been identified (Kramvis et al., 2005). Eight genotypes 
(A-H) of HBV can be defined by a nucleotide divergence in the region of 8% over the 
entire HBV genome and >4% over the S region (Norder et al., 1992a; Norder et al., 
1992b). The importance of HBV genotypes has become increasingly significant as their 
influence on chronic liver disease and response to antiviral therapies has become apparent 
(Akuta & Kumada, 2005; Kramvis & Kew, 2005).  
 
HBV genotypes have distinct geographical distributions, which may alter over time and 
because of human migration patterns (Fung & Lok, 2004). Genotype A prevails in North 
America, Africa, India and North Western Europe (Norder et al., 1993; Akuta & 
Kumada, 2005) and has a characteristic 6 nucleotide insert at the carboxy-terminal end of 
the core gene, which is absent in other genotypes (Kramvis et al., 2005). Complete 
genomic analysis has led to the further classification of genotype A into two 
subgenotypes, A1 and A2. A1 differs from A2 in that it has distinct sequence 
characteristics in all ORF’s and transcription regulatory elements (Kimbi et al., 2004). 
Moreover, complete sequence analysis of HBV isolates belonging to subgenotype A1 
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have demonstrated unique sequence characteristics suggesting that A1 has been endemic 
to the South African Black population for a long time (Kimbi et al., 2004).  Subgenotype 
A2 has been reported to be widely distributed in European countries and the USA, 
whereas A1 prevails in sub-Saharan Africa (Tanaka et al., 2004). 
 
Two subgenotypes of genotype B exist, both with distinct geographical distributions. 
Subgenotype B1 predominates in Japan whilst B2, which has a genotype C recombinant 
region overlapping the precore/core ORF, is found in Asia (Sagauchi et al., 2002). 
Genotype C is also subgenotyped into two groups, C1 and C2 and is mainly found in 
Southeast Asia, Japan and Oceania, whilst genotype D is generally found worldwide but 
is more common in the Mediterranean countries (Kimbi et al., 2004; Akuta & Kumada, 
2005).  
 
Genotype E is restricted to Africa and genotype F is found in Central and South America 
amongst the aboriginal people (Kao, 2002; Sumi et al., 2002; Kimbi et al., 2004). 
Genotype G has been identified in France and North America (Kao, 2002), with genotype 
H predominating in Central America (Kimbi et al, 2004).  
 
In regions where more than one genotype circulates, coinfection with different genotypes 
may occur in both children and adults as a result of multiple exposures or superinfection 
(Kramvis et al., 2005). This may be seen in genotype D which can coexist with genotype 
A in South Africa even though A is the predominant genotype.  
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There are currently four major HBV serotypes, or antigenic determinants of HBsAg 
based on antigenic heterogeneity (Kramvis et al., 2005), namely adw, ayw, adr, and ayr 
(Kao, 2002, Kramvis et al., 2005). Generally, adw serotypes are found in genotypes A, B, 
C, F and G, whilst genomes encoding adr and ayr may also occur in genotype C (Kao, 
2002). Serotype ayw is found in genotypes A-E (Kramvis et al., 2005).  
 
 
1.2 CHRONIC HBV INFECTION 
 
Chronic hepatitis B infection can be defined as a necroinflammatory lesion of the liver 
that lasts longer than 6 months and is associated with the presence of HBV markers of 
replication and virus-induced liver disease (Brunetto et al., 1993). It is one of the leading 
causes of morbidity and mortality worldwide (Ozgenc et al., 2004). Despite the progress 
of mass vaccination programs in recent years to control HBV, there are still over 350 
million chronically infected individuals worldwide (Papatheodoridis and Hadziyannis, 
2001; Flink et al., 2005). The evolution of HBV infection into either acute or chronic 
infection is directed by both viral and host factors, which are involved in influencing host 
immunotolerance and susceptibility, as well as the likelihood of the virus persisting or 
being eliminated (Brunetto et al., 1995).  
 
On the basis of virus-host interactions, the natural history of the infection can be divided 
into three phases (Chen, 1993):  
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 Immune tolerant phase: patients are HBeAg-positive and have high HBV DNA 
levels in the serum, are asymptomatic with normal serum alanine 
aminotransferase (ALT) levels and minimal histological activity in the liver. 
 Immune clearance phase: a proportion of the asymptomatic carriers show 
symptoms of acute hepatitis B. 
 Low-replicative or integration phase: seroconversion from HBeAg-positivity to 
anti-HBe positivity, with persistence of HBsAg and no liver disease. 
Chronic HBV infection has a variable course and outcome. A large proportion of infected 
individuals have a milder course associated with a reduction in HBV replication, leading 
to a loss in serum HBV DNA and seroconversion of HBeAg to e antibody (anti-HBe) 
(Papatheodoridis and Hadziyannis, 2001; Sumi et al., 2002). When HBV replication 
ceases and is associated with HBeAg seroconversion to anti-HBe, there is a transition to 
asymptomatic carrier status (Brunetto et al., 1993).  
 
Spontaneous reactivation is frequently seen during the course of chronic HBV infection 
and involves the reappearance of HBeAg and/or HBV DNA after a period in which they 
were negative, as well as a rise in serum ALT levels (Laskus et al., 1994). More severe 
forms are associated with a poorer outcome of infection. A subset of patients with 
HBeAg negative chronic hepatitis B, are found to have persistent viremia resulting from a 
continuation of viral replication. This form of HBV infection leads to chronic liver 
necroinflammation and progressive fibrosis, and is associated with the selection of 
replication competent pre-core mutants unable to produce HBeAg (Papatheodoridis and 
Hadziyannis, 2001).  
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It has also been suggested that viral persistence may be due to immune selection pressure 
of cytotoxic T cells and T helper cell responses in chronic HBV infection, which leads to 
mutations in HBeAg and human leukocyte antigen (HLA) class I and II restricted T cell 
epitopes (Cabrerizo et al., 1999). 
 
 
1.2.1 Chronic HBV infection in children 
 
The majority of chronic HBV carriers acquired their infections during childhood. Asia 
and Africa for example, where HBV is highly endemic, carry a high rate of infection in 
young children because of maternal-infant or early childhood transmission (Broderick 
and Jonas, 2003).  In contrast, in Western developed countries, HBV infection is 
uncommon in children and is mostly a disease of adulthood (Sokal et al., 1998).  
 
HBV infection acquired at an early age has three distinct phases; a high replicative 
immune tolerance phase and little liver inflammation, an immune response phase leading 
to inflammation and decreased viremia levels seen by a loss in HBeAg, and an immune 
surveillance phase with no or mild inflammation and low or undetectable replication 
(Lindh et al, 2001).  In neonates, infection is usually asymptomatic. Infections are less 
likely to become chronic in neonates infected peri-natally, if the mother is anti-HBe 
positive (Broderick and Jonas, 2003). The proportion of individuals who do develop 
chronic HBV infection also varies with age of infection, as >90% of neonates, 1-5% of 
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adults and an intermediate frequency of young children will become chronically infected 
(Broderick and Jonas, 2003). 
 
 
1.3 HBV-ASSOCIATED MEMBRANOUS NEPHROPATHY 
 
Membranous nephropathy is a kidney disorder characterized by the thickening of the 
capillary walls of the glomerular basement membrane by immune complexes, leading to 
the disruption of kidney function and protein leak into the urine as a direct result of 
inflammation of the glomerulus (Figure 1.7).  
 
 
 
Figure 1.7: Haematoxylin and eosin stain of HBV-associated MN showing the thickened capillary 
walls of the glomerular basement membrane. 
(http://oac.med.jhmi.edu/Pathology/Kidney/NephrSyn/082A_Full.html) 
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The cause of MN is unknown, but it is postulated to be associated with certain 
aetiological agents such as viruses, bacteria, parasites, autoimmune diseases and certain 
drugs (Dreyer, 1984).  
 
Involvement of chronic HBV infection in the pathogenesis of human renal diseases has 
been reported since 1971 (Combes et al., 1971), and has been associated with clinical 
manifestations ranging from transient proteinuria to overt nephritis or nephrotic 
syndrome (Lai & Lai, 1991). This is possibly due to the continued release of viral 
antigens into the bloodstream during HBV infection, providing an ideal setting for the 
development of immune complex-mediated MN (Dreyer, 1984). Chronic HBV carriage 
has been strongly associated on clinical, epidemiological, and immunological evidence 
with the occurrence of MN, particularly in children (Combes et al., 1971; Takekoshi et 
al., 1978).  
 
Studies have shown that HBV-associated nephropathy, particularly membranous 
nephropathy, is a major cause of nephrotic syndrome in Black children in South Africa 
(Wiggelinkhuizen et al., 1983; Bhimma et al., 1998; Bhimma et al., 2002b).  In a 
previous study they tested the hypothesis that family members and household contacts of 
children with HBV associated MN (HBVMN) would have a prevalence of HBV carriage 
higher than population controls and which would be associated with significant 
proteinuria.  A high prevalence of HBV carrier-state (37%) and asymptomatic proteinuria 
(28%) in families and household contacts of children with HBVMN was shown (Bhimma 
et al., 1999), but contrary to expectations there was no correlation among family 
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members and household contacts between HBV markers and abnormal proteinuria 
(Bhimma et al., 1999).   
 
1.4 INTERFERON TREATMENT FOR HBV INFECTION 
1.4.1 Background 
 
To control the spread of HBV infection in South Africa, the hepatitis B vaccine was 
incorporated into the Expanded Programme on Immunization (EPI) as part of routine 
childhood immunization, in 1995 (Mphahlele et al., 2002). Although these mass 
vaccination programs have begun to control the spread of HBV, therapeutic intervention 
is the only option for those with established chronic HBV-associated disease.  
 
The use of interferon to inhibit viral growth was first demonstrated in 1976 by 
Greensberg (Greensberg et al., 1976). Since then, its therapeutic value has been widely 
used in the treatment of chronic HBV infection, due to its ability to interfere with viral 
replication and production.  
 
IFN, a naturally occurring cytokine in the body, has antiviral, antiproliferative, 
antifibrotic and immunomodulating activity (Manns, 2002; Liaw, 2003). The IFN 
pathway is initiated when a cell is infected by a virus. Viral gene products will induce the 
synthesis and secretion of IFNs, which bind to extracellular domains of cell surface 
receptors and activate IFN-stimulated genes (ISG), whose products will inhibit viral 
replication and activate a global antiviral state (Sen, 2001).  
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Interferons can be divided into two subfamilies, namely the type I family, of which IFNα, 
-β, -ω and -τ are structurally related members, and the type II family, of which IFNγ is a 
member (Sen, 2001). All type I IFNs are secreted proteins and IFNα in particular, 
formerly known as leukocyte IFN, has four conserved cysteine residues which form 
intramolecular disulphide bonds, necessary for maintaining the biological activity of the 
protein (Sen, 2001). Recombinant forms of IFNα, for example IFNα-2a and IFNα-2b, are 
used to treat chronic HBV infection. 
 
IFNs immunomodulating effect includes mediating the expression of major 
histocompatability complex antigens, specifically that of the human leukocyte class I 
antigens on the surface of infected cells (Helvaci et al., 2004), and promoting the activity 
of macrophages and cytotoxic T cells to clear virally infected hepatocytes (Manns, 2002). 
Its antiviral activity involves the inhibition of viral penetration, replication and release 
from hepatocytes (Manns, 2002). Thus, the interaction of IFN with the cytokine cascade 
and T cell system is the key to its mode of action (Tilg, 1997).  
 
It has been suggested that sustained response to HBV treatment can only be achieved by 
induction of the host immune response (Janssen, 2005). Therefore, IFN is theoretically an 
ideal treatment for HBV infection. This however, has not proved to be the case. 
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1.4.2 Response rates to IFN treatment 
 
The short-term goal of any chronic HBV treatment is, first and foremost, to relieve any 
symptoms, reduce hepatic disease activity and to normalize ALT levels by making sure 
that there is a loss of HBeAg and/or HBV DNA (Liaw, 2003). The ultimate goal is to 
prevent cirrhosis of the liver and HCC (Manns, 2002).  
 
Response to IFN has been defined as a loss in HBeAg and HBV DNA, but many 
responders continue to show HBsAg and HBV DNA in serum (Lindh et al, 2001). 
Response rates do however vary, with only 33% of patients treated with IFN losing 
HBeAg (Saltik-Temizel, 2004). Only 25-40% of chronic HBV infected patients treated 
with a 4 to 6 month course of IFNα therapy have been shown to achieve sustained 
remission (King et al., 2002). In 1993, a meta-analysis of all studies showed IFNα 
therapy was beneficial in some HBeAg-positive patients who were treated for three to six 
months (Al-Wakeel et al., 1999).  Treated patients were much more likely to seroconvert 
to anti-HBeAg and to show normalization of liver enzymes (ALT) than controls. 
Obviously, in the case of HBeAg-negative cases, seroconversion to anti-HBeAg would 
be irrelevant and treatment responses including decreased serum HBV DNA to levels 
undetectable by polymerase chain reaction assays and normalization of ALT values 
would be measured.   
 
Children and adults have differences in immune tolerance and the rate of progression of 
liver disease because of differences in age at the time of infection, as well as differences 
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in the mode of transmission.  Therefore studies of treatments for chronic HBV infection 
in adults cannot be directly extrapolated to children (Broderick & Jonas, 2003). The 
treatment of chronic HBV infection in children, with IFN is thus unclear. It is apparent 
that adult-onset HBV infection will respond better to treatment than neonatal infection 
(Manns, 2002).  
 
IFNα treatment of chronic HBV infection in children in Western countries leads to a loss 
of HBV DNA or HBeAg seroconversion in 20 to 58% as compared with 8 to 17% in 
controls (Barbera et al., 1994; Vajro et al., 1996; Sokal et al., 1998).  This was 
demonstrated in a study carried out on 36 white children in whom a 50% response rate 
was seen after a 6 month course of therapy and was accompanied by a loss of HBV DNA 
and HBeAg and a decrease in serum ALT levels (Ruiz-Moreno et al., 1991). Similar 
studies done on Chinese chronically infected children showed no differences in outcome 
between placebo and IFN treated patients (Lai et al., 1987). Success rates are therefore 
not as high for the treatment of children in southeast Asian countries, most of whom were 
perinatally infected; only 3% to 17% clear HBV DNA or seroconvert from HBeAg to 
anti-HBe (Lai et al., 1987).   
 
Even though HBV is hyperendemic to sub-Saharan Africa, only a limited number of 
studies have been carried out to determine the efficacy of IFNα treatment of HBV 
infection in this area. In 1986, Dusheiko and his colleagues elucidated the efficacy of 
recombinant IFNα treatment on South African chronic HBV patients. All 28 patients 
tested were positive for HBsAg, HBeAg and HBV DNA at the onset of treatment. 
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However, at completion, inhibition of HBV replication and disappearance of HBeAg and 
HBsAg was only seen in 18% of patients (Dusheiko et al., 1986). 
 
In a study, carried out by Bhimma and colleagues (Bhimma et al., 2002a), twenty-four 
Black children with biopsy-proven HBV-associated nephropathy were recruited during 
the period April 1997 to June 1999 and treated with IFNα-2b for 16 weeks. Five children 
defaulted treatment and were therefore excluded from the study. A control group made up 
of 20 patients not receiving treatment was followed up for the same period of time.  
Response to treatment was defined as loss of HBeAg, decrease in proteinuria and 
prevention of deterioration in renal and liver function. By 40 weeks, ten (52.6%) of the 
treated children had responded to treatment with clearance of HBeAg.  All of the 
responders demonstrated remission of proteinuria, 90% maintained normal renal function 
and 1 (10%) showed improvement of renal function.  There was also a decrease of HBV 
DNA levels in this group. Nine patients did not clear HBeAg; none showed remission of 
proteinuria; 2 showed deterioration of renal function. The dominant HBV population in 
all 19 patients belonged to genotype A, the major genotype found in southern African 
Blacks. It was found that liver enzymes rose during treatment but subsequently declined 
irrespective of response. Only 5% of the control group showed spontaneous clearance of 
HBeAg, but none showed remission of proteinuria. It was therefore concluded that some 
Black children with HBV-associated nephropathy show accelerated clearance of HBeAg 
with remission of proteinuria following treatment with IFNα-2b. 
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1.4.3 Factors contributing to response 
 
Considering the fact that IFN treatment is expensive, is administered by injection, may 
have side-effects and can be poorly tolerated, the ability to predict treatment response is 
important in a clinical setting (Kramvis & Kew, 2005). Viral heterogeneity as well as 
host factors such as age, sex, race and immune competence status may all affect response 
to IFN therapy (Brunetto et al., 1993). 
 
1.4.3.1 Host Factors 
 
Certain factors within the host may predict a high likelihood of a beneficial response to 
IFN therapy (Sokal et al., 1998). These factors include high levels of ALT and low HBV 
DNA levels in the serum at start of treatment. According to Lai et al (1987), raised ALT 
levels in IFN treated patients reflect the hosts attempt to mount an immune response 
against the infection, whereas normal ALT levels reflect latent disease. In children, 
conflicting results have been found. In a study on Chinese children, low serum ALT 
levels and high HBV DNA levels seemed to predict low response to IFN therapy (Lai et 
al., 1987), whereas other studies have demonstrated that children with high ALT levels 
correlated with a better response to IFN therapy (Sokal et al., 1998; Moreno et al., 1991).   
Other host factors that may play a role in predicting good response include female gender 
and active fibrosis on liver specimens in HBeAg-positive chronic HBV patients (King et 
al., 2002). 
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Together with conventional predictors of treatment response, single nucleotide 
polymorphisms (SNPs) may also be useful predictive markers for response to therapy.  
With regard to the host’s genetic background, SNPs have been found to play a role in 
disease and treatment response via the host immune and antiviral response (King et al., 
2002). Specifically, polymorphisms in the IFN pathway have been identified which may 
play a role in IFN response in patients with chronic HBV infection. 
 
1.4.3.2 Molecular Virological Factors    
 
The molecular virological factors that contribute to the responsiveness of HBV infection 
to IFN treatment are largely unknown and may play a significant role in predicting 
whether IFN can be used effectively for treatment. To date the most important viral factor 
that has convincingly been shown to determine the response to IFN, is the pretreatment 
HBV DNA titre; the lower the titre the better the response (Aikawa et al., 1995).      
 
HBe antibody and HBV DNA-positive chronic HBV infection is a separate clinical entity 
from HBeAg-positive chronic HBV infection (Saruc et al., 2003). Only 30-40% of 
HBeAg-positive patients and 10-50% of HBeAg-negative patients have been reported to 
respond to IFN therapy (Erhardt et al., 2000). A number of studies have been carried out 
to address the significance of HBeAg status for the long term outcome of IFN therapy. 
Most studies have shown that in HBeAg-positive patients, low ALT levels, high HBV 
DNA replication and a long duration of disease is associated with low IFN response rates 
(Erhardt et al., 2000). It has been reported by Lampertico et al (1997), that a sustained 
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virological and clinical response was achieved with prolonged IFNα treatment in HBeAg-
negative or anti-HBe positive patients. Similarly, sustained response rates of 25-50% 
have been reported by other studies on HBeAg-negative patients (Aikawa et al., 1995; 
Zhang et al., 1996). These results seem to correlate with a study in which approximately 
30% of HBeAg-negative patients with chronic hepatitis B virus infection showed lasting 
suppression of infection after 24 months of IFN treatment (Lampertico et al., 2003). 
However, these data seem to be in disparity with a study in which HBeAg-negative status 
was said to be related to a high relapse rate and poor sustained response of 10% to IFN 
therapy (Aikawa et al., 1995). Another group concluded that a sustained response to IFN 
was independent of HBeAg status (Erhardt et al., 2000).    
 
HBeAg is coded for by the precore/core ORF and transcription of the precore/core 
mRNA is controlled by the basic core promoter (BCP).  Therefore it has been postulated 
that mutations in either the BCP or the precore/core region could affect responsiveness of 
IFN treatment.   
 
The presence of mutations within the BCP, namely, A1762T / G1764A and single 
substitutions at position 1751 through 1755, have been hypothesized to play a role in 
HBV replication and HBeAg synthesis (Zampino et al., 2002). Moreover, these 
mutations have been shown to correlate with response to IFN treatment in some studies 
(Erhardt et al., 2000; Zampino et al., 2002) but not in others (Kao et al., 2000; Hannoun 
et al., 2002a). Low HBV DNA levels and elevated ALT levels in addition the BCP 
 37
mutations have been proposed to be favorable factors of response in IFN-induced anti-
HBe seroconversion (Zampino et al., 2002).  
 
One study found that response to IFN had little to do with BCP mutations, but was 
merely as a result of viral loads, thus not supporting the hypothesis that BCP mutations 
are indicative of favorable IFN response rates (Shindo et al., 1999). 
 
The data on the relevance of precore mutants and their influence on the long term 
response to IFN are also inconclusive.  In some studies precore mutants were considered 
to be necessary for response to IFN (Takeda et al., 1990; Aikawa et al., 1995; Lok et al., 
1995) . One such study reported a shift in pattern from wild-type to the precore mutant 
following IFN treatment in 6 out of 9 responding patients compared with 0 out of 9 non-
responders, suggesting that long term IFN response is associated with the take-over of 
precore mutants (Lampertico et al., 1995). These data differ with respect to other studies 
which showed that precore mutants do not have prognostic value for virus elimination 
following IFN therapy in HBeAg-positive or HBeAg–negative patients (Xu et al., 1992; 
Fattovich et al., 1995).  Numerous reports have also indicated that the precore mutant is 
resistant to IFN (Brunetto et al., 1993; Fattovich et al., 1995).  
 
Because of selection pressure of IFN therapy, mutations may also arise in the polymerase 
gene of HBV. There are however no ‘signature’ mutations in this region which can be 
correlated with IFNα response (Chen et al., 2003). Likewise, because of the low 
emergence of mutations in the X region of HBV during IFN therapy, this region does not 
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seem to be a major determinant of response (Hannoun et al., 2002a). These differences in 
responsiveness to IFN treatment are probably the result of different genotypes of the 
virus and therefore an analysis of how various mutations influence the therapeutic 
response to IFN also requires knowledge about the genotype (Lindh, 1997).  
 
In one study, a response rate of 41% compared with that of 15% was seen in genotype B 
compared with genotype C respectively, following IFNα-2b treatment (Kao et al., 2000). 
In a similar study, a higher response rate was observed in patients infected with genotype 
A than those infected with genotype D/E (Zhang et al., 1996). Similarly, Erhardt et al 
(2000), reported that a study of 64 German patients revealed that the rate of IFN-induced 
HBeAg seroconversion was higher among patients infected with genotype A (37%) than 
those infected with genotype D (6%). Further investigation revealed that sustained 
response to IFN therapy was also higher in genotype A compared with that of genotype D 
infected patients (49% vs 26%) (Erhardt et al., 2005). In contrast, in a study carried out in 
Japan, IFN was given to 7 patients with prolonged HBV infection, and 4 of them 
responded. Of the 4 responders, one was infected with HBV genotype B and three with 
genotype C.  HBsAg persisted in the remaining 3 patients all of whom were infected with 
HBV genotype A, and HBeAg remained positive in one of them (Kobayashi et al., 2002).  
Following IFN treatment, genotype switching has been observed as a result of infection 
with a mixture of genotypes prior to treatment (Gerner et al., 1998; Hannoun et al., 
2002a; Hannoun et al., 2002b). The minor quasispecies populations were, however, not 
detected by either standard genotyping assays or direct sequencing but were detected 
using either a genotypic-specific polymerase chain reaction (PCR) and restriction 
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fragment length polymorphism (RFLP) or cloning (Kramvis & Kew, 2005). Genotype 
shifts suggest that genotypes are influenced by IFN differently (Hannoun et al., 2002b). 
IFN treatment may zone the immune system towards the major strain, thus allowing the 
minor strains to take over or increase (Hannoun et al., 2002b).   
Thus, a thorough knowledge of the HBV strains circulating within a specific 
geographical region is required because studies from one geographical region cannot be 
directly extrapolated to regions where the circulating genotypes are different.  
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1.5 RATIONALE AND AIMS OF THE STUDY 
 
Many studies have been undertaken to elucidate the role of HBV mutations and their 
subsequent effect on patient response to IFN therapy.  The precore/core, polymerase and 
X genes in particular, have been sequenced and analyzed in patients treated with IFN. 
However, little is known about the effect, if any, of surface gene mutations on IFN 
response and vice versa.  
 
The objective of this pilot study was therefore to sequence the complete S open reading 
frame of HBV isolated from South African Black children with membranous 
nephropathy before, during and after treatment with IFNα-2b, in order to determine 
whether: 
• mutations in the S gene of  HBV isolates are useful predictive markers for 
IFN response; 
• the emergence of mutants during treatment influences the outcome; 
• there are minor populations of mutant genomes that influence the 
outcome. 
 
This will allow us to establish whether differences in the efficacy of IFNα therapy in this 
group of patients are due, at least partly, to viral heterogeneity in the S gene because host 
factors may also be important determinants.   
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Chapter 2: MATERIALS AND METHODS 
2.1 PATIENTS 
 
Twenty-four Black patients were recruited from the Renal Clinic at the King Edward VIII 
Hospital Durban, during the period April 1997 to June 1999. Nineteen of these completed 
the full course of therapy. The remaining 5 patients defaulted treatment, completing less 
than 80% of the course of treatment, and were excluded from the primary analysis. All 
patients recruited into the study had nephrotic syndrome diagnosed in accordance with 
the standard criteria (Barratt et al., 1994); all were carriers of HBsAg and HBeAg for a 
minimum period of 6 months before entry into the study.  Clinical examination and 
appropriate investigations were done to exclude other secondary causes of nephrotic 
syndrome (Bhimma et al., 2002a).  
 
2.1.1 Interferon Treatment 
 
This was a prospective, open-labeled, observational study of the use of IFNα-2b in Black 
African children.  IFNα-2b (Intron A, Shering-Plough Co., USA) in a dose of 10 million 
units/m2 (maximum 10 million units/dose) was administered subcutaneously 3 times per 
week by trained health care professionals to all study subjects.   Before starting treatment, 
a test dose of 3 million units was given to all subjects in hospital with full resuscitation 
facilities available.  Patients were treated for 16 weeks.  Treatment dosage and adverse 
events were recorded by the health professional on a report card carried by the parent or 
guardian.  Proteinuria, HBV status, liver function tests (including liver enzymes), and 
 42
renal function were recorded on weeks 8, 16 and 40 on the record cards.  The card was 
monitored by the principal investigator and returned to him at the end of treatment. 
IFNα-2b therapy was discontinued if the child developed severe neurological symptoms 
(convulsions, severe psychiatric symptoms) or haematological disturbances (white cell 
count < 1.5 x 109/l; haemoglobin <7.0 x 109 g/l or platelets < 150 x 109/l) (Bhimma et al., 
2002a).  
 
None of the patients had been treated with steroids or with cytotoxic agents.   
Symptomatic oedema was treated with salt restriction and diuretics.  In those patients 
unresponsive to these measures, salt free albumin solution (20%) in combination with 
diuretics was used.  Hypertension was controlled using angiotensin converting enzyme 
antagonists, thiazide diuretics, and calcium ion antagonists, singly or in combination. 
 
2.1.2 Outcome Measures 
 
These included HBV status, clinical criteria, and biochemical assessment of renal and 
liver function.  Clinical criteria assessed were oedema, hypertension, and proteinuria.  
Histological assessment of renal and hepatic status on follow-up renal and liver biopsies 
was not undertaken because of failure to obtain ethical consent for these procedures from 
the University of Natal Research Ethics Committee (Bhimma et al., 2002a).  
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2.1.3 HBV Determination 
 
HBV status determination using 3rd generation Elisa and assays of HBV DNA using 
AMPLICOR to determine HBV genomes/ml were undertaken at study entry, 8, 16 and 40 
weeks.  Using AMPLICOR, the upper threshold was defined as >4 x107 genomes/ml and 
the lower limit as 400 genomes/ml.  A virological response was identified as a reduction 
of HBV DNA to <106 copies/ml, including a 97% (1.5 logs) reduction of viremia (Lindh 
et al., 2001). 
 
All subjects also had hepatitis C virus (HCV) testing using both microparticle enzyme 
immunoassay (MEIA) for detection of antibodies (Abbott Imx ® HCC version 3.0) and 
reverse transcriptase polymerase chain reaction (RT-PCR) (Smuts & Kannemeyer, 1995).  
Human immunodeficiency virus (HIV) status was determined using Enzyme Linked 
Immunosorbent Assay (Abbott Laboratories recombinant HIV 1-2 ®, 3rd generation EIA) 
with confirmation by immunofluorescence assay (Viron ®) (Bhimma et al., 2002a). 
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Patients divided into 3 categories based on ALT, serum HBV load and 
HBeAg determination  
 
 
REVERTERS 
(n=4) 
 
 
RESPONDERS 
(n=10) 
NON-RESPONDERS 
(n=5)
 
 
 
 
 
8 patients: HBV 
DNA levels 
decreased 
2 patients: Levels 
unchanged 
All cleared HBeAg 
HBV DNA levels high, 
no HBeAg clearance. 
Remained at relapse at 
week 40 
3 patients: no change in 
HBV DNA levels. 1 
patient: decline in HBV 
DNA. Cleared HBeAg 
then reverted. 
 
DNA extracted from one 
responder, one reverter and one 
non-responder at the following 
time points: 
• T0 - before start of IFN 
(baseline) 
• T2 – 4 weeks 
• T4 – 8 weeks 
• T6 – 40 weeks 
 
 
 
 
 
 
Figure 2.1: Flow diagram summarizing the serum samples used in the present study.  
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2.2 EXTRACTION OF HBV DNA FROM SERUM 
 
Serum obtained from patients was used to extract HBV DNA using the QIAamp® DNA 
Blood Mini Kit (QIAGEN, GmbH, Hilden, Germany), as per manufacturer’s instructions. 
This kit allows for the purification of total DNA, free of protein, nucleases and other 
contaminants or inhibitors, from blood, plasma, serum or other body fluids. 
 
Before starting, the samples and the buffers were equilibrated to room temperature, and a 
heating block was pre-heated to 56ºC. 200 μl of the serum sample was added to a 1.5 ml 
Eppendorff tube, together with 20 μl QIAGEN Protease (Proteinase K). 200 μl Buffer AL 
was then added to the sample and the mixture pulse-vortexed for 15 sec to mix, followed 
by 10 min incubation at 56ºC.  200 μl of absolute ethanol was then added to the sample 
and again mixed by pulse-vortexing for 15 sec. The mixture was then carefully applied to 
a QIAamp Spin Column and centrifuged at 8 000 rpm for 1 min. The column was placed 
in a clean collection tube and 500 μl Buffer AW1 added. Centrifugation was again carried 
out at 8 000 rpm for 1 min and the column placed in a clean collection tube. After 
addition of 500 μl Buffer AW2, the QIAamp Spin Column was centrifuged at 14 000 rpm 
for 3 min. To eliminate any chance of Buffer AW2 carryover, an optional centrifugation 
step was carried out for an extra min at 14 000 rpm. The QIAamp Spin Column was then 
placed in a sterile 1.5ml Eppendorff tube, 50 μl best quality water (BQW) added directly 
to the column and incubated for 5 min at room temperature. The DNA was eluted by 
centrifugation for 1 min at 8 000 rpm and stored at -20ºC until needed.   
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In addition to the serum sample, a negative control consisting of BQW was included in 
the extraction procedure to check for contamination.  
 
2.3 POLYMERASE CHAIN REACTION (PCR) 
 
PCR is a highly specific and sensitive method designed to amplify large quantities of a 
DNA sequence without the use of cloning. The basic three steps of PCR involve a 
denaturation step in which double stranded DNA is denatured to single stranded DNA by 
heating to 94ºC, an annealing step in which the primers anneal to either side of the target 
sequence via their complementary bases and lastly, the extension of the target sequence 
by a DNA polymerase. Each of the aforementioned steps occurs at different temperatures 
in a thermal-cycler, resulting in an exponential increase in the target DNA. 
 
2.3.1 Full-length PCR 
 
The full genome of HBV was amplified from extracted DNA in a 25 μl reaction, on the 
Robocycler® Gradient 40 Temperature Cycler (Stratagene, Whitehead Scientific, La 
Jolla, CA) using the method described by Günther et al (1995).  
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Table 2.1: Oligonucleotide primers for full-length PCR 
 Primer          Nucleotide                      Primer Sequence*                             Size of  
                        position                                                                                 amplicon (bp)    
    
  P1.1 (+)       1821 - 1841         5’ TTTTTCACCTCTGCCTAATCA 3’ 
                                                                                                                             3215 
Abbreviations: (+) sense, (-) anti-sense 
  P2.1 (-)        1825 - 1806         5’ AAAAAGTTGCATGGTGCAGG 3’ 
* Nucleotide position of HBV adw genome (GenBank accession number AY233276), where position 1 is 
the EcoRI cleavage site. 
 
Because the amplification was carried out as a ‘hot-start’ PCR, the reaction mixture 
consisted of two components: 
•  5 µl of HBV DNA was amplified by PCR in a 15 μl reaction mix containing; 
10.3 µl BQW, 2 µl 10X Expand High Fidelity Buffer with 1.5 mM MgCl2, 0.2 µl 
25 mM dNTP’s and 1.25 µl each of the primers P1.1 (1821-1841 from EcoRI site) 
and P2.1 (1825-1806 from EcoRI site), respectively (Table 2.1) in a 0.5 ml 
Eppendorff tube. A drop of sterile mineral oil was added to each tube to prevent 
evaporation of the sample. 
• The enzyme mix, made up in a separate tube, consisted of 3.75 µl BQW, 0.5 µl 
10X Expand High Fidelity Buffer with 1.5 mM MgCl2, and 0.75 µl Expand High 
Fidelity Enzyme mix (Roche Applied Science, Germany).  
 
To perform a ‘hot-start’ PCR, the premix containing the DNA was denatured at 94ºC for 
2 min and 40 sec, followed by the addition of 5 µl of the enzyme mix during the first 
annealing step of 58ºC for 1 min 30 sec. This was followed by 40 cycles of amplification 
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with a cycle profile of 94oC for 40 sec (denaturation), 58oC for 90 sec (annealing), and 
68oC for 3 min with an increment of 2 min after every 10 cycles (extension). 
 
A positive control as well as a negative control consisting of a HBV-positive sample and 
BQW, respectively was included in all PCR reactions.  
 
2.3.2 Amplification of the Surface Region of HBV 
 
A nested PCR was carried out to amplify the entire S region of HBV (preS1/S2/S region). 
This PCR was carried out on the GeneAmp PCR System 9600 Perkin Elmer 
(Biotechnology, U.S.A). 
 
First round PCR consisted of 22.5 µl of a reaction mixture containing 15.4 µl BQW, 2.5 
µl 10X Promega Buffer, 1.5 µl 25 mM MgCl2, 0.5 µl 40mM dNTP’s (10 mM each 
dNTP), 1.25 µl each of the outer primers, 2408F and 1327R, respectively (Table 2.2), and 
0.1 µl Promega Taq DNA Polymerase (Promega, Madison, WI) in a 0.2 ml Eppendorff 
tube. To this mixture, 2.5 µl of the HBV DNA was added to bring the total reaction 
mixture to 25 µl.  
 
PCR cycling for the first round involved 40 cycles of denaturation at 94ºC for 60 sec, 
annealing at 66ºC for 5 mins and extension at 72ºC for 3min. 5 μl of the above reaction 
was then added to a second round mixture containing; 30.8 µl BQW, 5 µl 10X Promega 
Buffer, 3 µl 25 mM MgCl2, 1 µl 40 mM dNTP’s (10 mM each dNTP), 2.5 µl each of the 
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inner primers 2800F and 1011R, respectively (Table 2.2), and 0.2 µl Promega Taq DNA 
Polymerase (Promega, Madison, WI) in a 0.2 ml Eppendorff tube. The second round 
cycling profile consisted of 40 cycles of denaturation at 94ºC for 60 sec, annealing at 
66ºC for 1 min and extension at 72ºC for 1 and a half mins.  
 
Table 2.2: Oligonucleotide primers for surface gene PCR 
  Primer                 Nucleotide                     Primer Sequence*                                Size of 
                                Position                                                                                amplicon (bp) 
 
Outer Primers             
   2408(+)             2408 - 2438        5’ TCTCAATCGCCGCGTCG 
                                                            CAGAAGATCTCAA 3’           
                                                                                                                                    2119 
   1327(-)              1327 - 1301        5’ CGATGAGTTTTGCTCCA 
                                                             GACCGGCTGC 3’ 
 
Inner Primers 
   2800(+)              2800 - 2834         5’ CACGTAGCGCATCATTTT 
                                                              GCGGGTCACCATATTCT 3’ 
                                                                                                                                    1411 
   1011(-)               1011 - 977           5’ CAAAAGACCACAATTCTT 
                                                               TGACATACTTTCCAAT 3’         
Abbreviations: (+) sense, (-) anti-sense 
 
* Nucleotide position of HBV adw genome (GenBank accession number AY233276), where position 1 is 
the EcoRI cleavage site. 
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2.4 VISUALIZATION OF PCR PRODUCTS 
 
Following PCR, the resulting DNA products were separated by size via electrophoresis 
on a 1% agarose gel containing ethidium bromide (Appendix D1). Sizes of PCR products 
were estimated relative to the migration patterns of a 1 kb DNA ladder (Promega, 
Madison, WI, USA) for the full-length PCR products and a 100 bp DNA ladder 
(Promega, Madison, WI, USA) for the surface gene PCR products. Products were 
visualized by placing the gel under ultraviolet light. 
  
2.5 CLONING OF HBV DNA 
 
The TOPO® XL PCR Cloning Kit (Invitrogen, Carlsbad, CA), is a quick (5 min), 
efficient, one-step cloning method for cloning PCR products. The TOPO® Cloning 
Reaction can be transferred directly into competent cells by chemical means. 
Recombinants are then selected by the disruption of the lethal E.coli gene, ccdB. 
Therefore, if the PCR product has correctly ligated to the vector containing the ccdB 
gene, expression of the gene is disrupted, allowing growth of positive recombinants upon 
plating.  
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2.5.1 Preparation of PCR products for cloning 
2.5.1.1 Addition of 3’A Overhangs 
 
Prior to cloning, 3’ deoxyadenosine (A) overhangs needed to be incorporated onto the 
full-length PCR product. This was achieved by adding 1 μl TaKaRa Ex Taq DNA 
Polymerase (TaKaRa Bio Inc., Japan) to the product and the incubating for 10 min at 
72ºC under mineral oil.  As this enzyme has nontemplate-dependent terminal transferase 
activity, it is able to add single A’s to the 3’ end of the PCR product generated after full-
length PCR. The plasmid vector (pCR®-XL-TOPO®) that was supplied in the TOPO® XL 
PCR Cloning Kit, is then linearized with the single 5’ deoxythymidine (T) overhangs. 
Thus the addition of the A’ overhangs onto the PCR product allows it to insert and ligate 
with the vector. This step was only needed for the full-length PCR products amplified 
using Expand High Fidelity Enzyme (Roche Applied Science, Germany) because this 
enzyme does not add on A’ overhangs. 
 
2.5.1.2 Purification of PCR products 
 
The amplified DNA was purified using the MinElute® Reaction Clean-up Kit (QIAGEN, 
GmbH, Hilden, Germany), in order to remove any enzymes, salts or nucleotides, which 
would affect the cloning efficiency. Following manufacturer’s instructions, the entire 
volume of PCR product was transferred to a new sterile Eppendorff tube. 300 μl Buffer 
ERC was then added and the sample and votexed to mix. A MinElute column which 
adsorbs all the DNA to the silica-membrane, was then placed in a collection tube, all the 
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sample was applied to the column and the mixture was centrifuged for 1 min at 14 000 
rpm. The flow-through was discarded and the column placed back in the collection tube. 
750 μl Buffer PE was then added and the sample was again centrifuged under the same 
conditions as before to ensure all impurities were washed away. To dry the column, the 
centrifugation step was once again repeated for 1 min at 14 000 rpm. The column was the 
placed in a new sterile 1.5ml Eppendorff tube and the collection tube discarded. 10 μl 
BQW was added to the column and incubated for 1 min to allow the water to absorb. This 
was followed by a centrifugation step of 1 min at 14 000 rpm to elute the DNA from the 
column, proceeding directly to the purification of the product from a gel.     
   
2.5.2 Gel Purification of PCR Product 
 
Purified amplicons were electrophoresed on a 0.8% crystal violet agarose gel (Appendix 
D1) together with a 1 kb and 100 bp molecular weight marker (Promega, Madison, WI, 
USA).  40 μl of the PCR product was loaded onto the gel with 8 μl 6X Crystal Violet 
Loading Buffer and allowed to run at ~53 volts for 1½ to 2 hours, or once the crystal 
violet in the gel had run about a quarter of the way up the gel. 
 
To excise the PCR product, the buffer was poured off and the gel placed on a fluorescent 
light box to help visualize the fragments. Using a new surgical blade, the band was 
carefully excised from the gel and placed into a sterile 1.5 ml Eppendorff tube. The 
volume of the agarose pieces was estimated by weighing the gel (1mg ~ 1μl), and 2.5 
times this volume of 6.6 M sodium iodide was added. By periodically shaking the tube 
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vigorously and incubating at 45ºC on a hot block, the agarose was completely dissolved 
in approximately 2 min. 1.5 volumes of Binding Buffer was then added to the tube at 
room temperature and mixed well. To isolate the PCR product from the agarose, all the 
above mixture was loaded onto an assembled S.N.A.P.™ purification column (A) and 
collection vial (B). This was then centrifuged at 4 000 rpm in a microcentrifuge for 30 
sec at room temperature. The liquid in the collection vial was then poured back into the 
column and again centrifuged for 30 sec at 4 000 rpm. The former step was repeated a 
third time to ensure all the DNA had bound to the column. After the third centrifugation, 
the liquid in the collection tube was discarded. 400 μl of 1X Final Wash was then added 
to the column and centrifuged as before for 30 sec. This step was repeated (400 μl new 
Final Wash) and the liquid in the collection tube (800 μl) was discarded. To dry the 
column resin, the column was centrifuged again at 14 000 rpm for 2 min, thereafter the 
column was transferred to a sterile 1.5 ml Eppendorff tube. To elute the DNA from the 
column, 40 μl TE buffer was added directly to the column and incubated for 1 min at 
room temperature to allow the buffer to absorb into the column. This was followed by a 
final centrifugation at 14 000 rpm for 1 min to elute the DNA from the column, after 
which the tube was placed on ice before proceeding to the next step. 
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2.5.3 TOPO® Cloning and Transformation 
 
To clone the PCR product into the pCR®-XL-TOPO® vector, a 5 μl TOPO® Cloning 
reaction was set up. 4 μl gel-purified PCR product was added to 1 μl pCR®-XL-TOPO® 
vector in a sterile Eppendorff tube. The reaction was mixed by gently tapping with a 
finger and then incubated for 5 min at room temperature. After the 5 min incubation, 1 μl 
of the 6X TOPO® Cloning Stop Solution was added and mixed by gently tapping for 
several sec at room temperature. The tube was then briefly centrifuged and placed on ice.  
 
To transform One Shot® TOP10 chemically competent cells, 2 μl of the TOPO® Cloning 
reaction was added into a vial of One Shot® TOP10 cells and gently mixed. This reaction 
was then incubated for 30 min on ice. After the incubation, the cells were heat-shocked 
for 30 sec at 42ºC without shaking, and then immediately transferred to ice for 2 min. 250 
μl of room temperature S.O.C. medium was then added followed by a 1 hour incubation 
at 37ºC on a shaker. Following incubation, the tube was placed on ice.  
 
50-150 μl from each transformation was then spread, using a glass spreader and aseptic 
techniques, on a prewarmed Luria-Bertani (LB) agar plate containing 50 μg/ml of the 
antibiotic kanamycin (Roche Diagnostics, GmbH, Mannheim, Germany) (Appendix D1). 
The plates were incubated overnight at 37ºC to allow for bacterial growth.  
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Individual cloned colonies, approximately 40 at a time, were aseptically restreaked using 
a sterile loop, onto new LB-Kanamycin plates and allowed to grow for 24 hours. Plates 
were then stored at 4ºC.     
 
2.6 ISOLATION OF CLONED DNA 
 
HBV DNA was extracted from the plasmid using the GenElute™ Plasmid MiniPrep Kit 
(Sigma-Aldrich, St Louis, MO, USA). This method allows for the isolation of plasmid 
DNA from recombinant E.coli cultures.  Prior to extraction, bacteria from the LB-
Kanamycin plates were inoculated into a 15 ml nunc tube containing 5 ml LB media and 
5 μl Kanamycin and shaken overnight at 37ºC. After 24 hours, the overnight culture was 
spun for 15 min in a centrifuge at 5 000 rpm to pellet the cells. The cells were then 
resuspended in 200 μl Resuspension Solution by vigorously pipetting up and down, and 
transferred to a sterile 1.5 ml Eppendorff tube. 200 μl Lysis Solution was added to lyse 
the resuspended cells and release the DNA, inverted gently to mix and allowed to clear 
for 5 min. 350 μl Neutralization Solution was then added and inverted 4 to 6 times to 
mix, in order to precipitate cell debris. The debris was pelleted out by centrifuging the 
mixture for 10 min at 14 000 rpm. 
 
To prepare the binding column in order to allow maximum binding of DNA, 500 μl 
Column Preparation Solution was added to the binding column in a collection tube, spun 
for 1 min at 14 000 rpm and the flow-through discarded. The plasmid DNA was then 
bound to the column by transferring all the cleared lysate into the binding column and 
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spinning for 1 min at 14 000 rpm. The flow-through was discarded and 500 μl Optional 
Wash Solution added to the column to remove all contaminants. The column was spun 
under the same conditions as before and the flow-through discarded. 750 μl Wash 
Solution was added, spun as before to discard flow-through and then spun an extra min at 
14 000 rpm to dry the column.  
 
To elute the purified plasmid DNA, the column was transferred to a new 1.5 ml 
collection tube and 50 μl BQW was added directly to the column. This was followed by a 
final spin at 14 000 rpm for 1 min. The concentrated plasmid DNA could be stored at -
20ºC until needed. A negative control consisting of only LB-Kanamycin was included in 
the procedure to ensure the sterility of the media.  
 
2.7 DIGESTION OF ISOLATED PLASMID DNA 
2.7.1 Restriction Endonucleases 
 
Restriction enzymes or restriction endonucleases, cleave DNA at a very specific site or 
recognition sequence. The recognition sequence is often a 6 base pair palindromic 
sequence, but some restriction enzymes recognize 4 or even 8 base pair sequences. 
Because on this sequence specificity, restriction enzymes are used to further characterize 
a particular DNA molecule by cutting the DNA into discrete fragments. The restricted 
DNA fragments can then be resolved by gel electrophoresis and the pattern the DNA 
fragments generate, produce a DNA ‘fingerprint’.  
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2.7.1.1 EcoRI Digestion 
 
Plasmid DNA was treated with the restriction enzyme EcoRI (Promega, Madison, WI), to 
check for the integration of the PCR product into the plasmid. A master mix of 4.9 μl 
BQW, 0.1 μl BSA, 1 μl Promega EcoRI Buffer and 1 μl Promega EcoRI enzyme 
(Promega, Madison, WI) per sample was added to 3 μl of the plasmid DNA. 1 drop of oil 
was added to the tube to prevent evaporation of sample. Digestion was carried out on a 
37ºC hot block for 2 hours, after which 4 μl bromophenol blue (Merck, Darmstadt, 
Germany) loading dye was added to stop the reaction. The result of the digestion was 
visualised by running 10 μl of the sample overnight at ~30V on a 1% agarose gel, 
together with 1 kb and 100 bp molecular weight markers (Promega, Madison, WI, USA). 
 
2.8 GENOTYPING 
 
Lindh genotyping is a novel method for genotyping HBV, making use of restriction 
fragment length polymorphism (RFLP), using the restriction enzymes Tsp509I 
(recognizes AATT) and HinfI (recognizes GANTC). 
 
2.8.1 PCR 
 
To amplify the DNA prior to genotyping, a 100 µl PCR reaction was set up in a 0.2 µl 
Eppendorff tube containing the following components: 64.8 µl BQW, 10 µl 10X NH4 
reaction buffer, 6 µl 50 mM MgCl2, 8 µl 20 mM dNTP’s, 5 µl each of the primers P7 and 
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P8 (Table 2.3), 0.2 µl 5u/µl Biotaq™ DNA Polymerase (Bioline, GmbH, Germany). To 
this reaction mix, 1 µl DNA was added.  
 
Table 2.3: Oligonucleotide primers for P7/P8 genotyping PCR 
  Primer       Nucleotide                         Primer Sequence*                             Size of 
                      position                                                                                  Amplicons (bp)
    
 P7(+)           256 - 278           5’ GTGGTGGACTTCTCTCAATTTTC 3’ 
                                                                                                                              541 
 P8(-)            796 -776            5’ CGGTATAAAGGGACTCACGAT 3’ 
 
Abbreviations: (+) sense, (-) anti-sense 
* Nucleotide position of HBV adw genome (GenBank accession number AY233276), where position 1 is 
the EcoRI cleavage site. 
 
Amplification was carried out on the Eppendorf Mastercycler® Gradient (Eppendorf, 
Hamburg, Germany). An initial denaturation step of 94ºC for 3 min was followed by 
amplification of the above reaction for 40 cycles with the following parameters: 
denaturation at 94ºC for 45 sec, annealing at 53ºC for 1 min and extension at 72ºC for 1 
and a half mins.  
 
2.8.2 RFLP assay for Genotyping 
 
A master mix was prepared for each of the enzymes, Hinf I (Promega, Madison, WI) and 
Tsp 509I (New England Biolabs, Beverly, MA), used for genotyping (Table 2.4).  
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Table 2.4: Master mixes for genotyping HBV clones 
 Hinf I (in µl) Tsp 509I (in µl) 
BQW 2.3 2.5 
10X Buffer 2 2 
Bovine serum albumin 0.2 / 
Restriction enzyme 0.5 0.5 
 
 
5 µl of the each of the master mixes was added to two separate 0.5 ml Eppendorff tubes, 
followed by 15 µl of the PCR product. A drop of sterile mineral oil was added to each 
tube to prevent evaporation of the product. Both reactions were incubated for 3 hours; 
Hinf I at 37ºC and Tsp 509I at 65ºC. After incubation, the reaction was terminated by the 
addition of 4 µl loading dye. 10 µl of the sample was then run on a 3% ethidium 
bromide-stained composite agarose gel (Appendix D1) overnight at ~30V, alongside 100 
bp and 1 kb molecular weight marker (Promega, Madison, WI, USA). The resulting 
restricted fragments were visualized under UV light.  
 
2.9 SUBGENOTYPING OF HBV 
 
In order to distinguish between subgenotypes A1 and A2 the method described by Kew et 
al (2005) was used. The following PCR reaction mix was set up in a 0.2 µl Eppendorff 
tube: 33.3 µl BQW, 5 µl 10X NH4 reaction buffer, 1.5 µl 50 mM MgCl2, 4 µl 10 mM 
dNTP’s, 0.5 µl each of the primers 521F and 1192R (Table 2.5)and 0.2 µl 5u/µl Biotaq™ 
 60
DNA Polymerase (Bioline, GmbH, Germany). To this reaction mix, 5 µl DNA was 
added.  
 
Table 2.5: Oligonucleotide primers for subgenotyping of HBV  
Primer          Nucleotide                        Primer Sequence*                            Size of 
                       Position                                                                                 amplicons (bp) 
 
  
 521(+)          521 - 541                5’CCTGCACGACTCCTGCTCAA 3’ 
                                                                                                                             671 
1192(-)         1192 -1173              5’CGTCAGCAAACACTTGGCAC 3’ 
Abbreviations: (+) sense, (-) anti-sense 
* Nucleotide position of HBV adw genome (GenBank accession number AY233276), where position 1 is 
the EcoRI cleavage site. 
 
An initial denaturation step of 94ºC for 3 min was followed by 40 cycles of denaturation 
at 94ºC for 45 sec, annealing at 60ºC for 1 min and extension at 72ºC for 1 and a half min 
on the Eppendorf Mastercycler® Gradient (Eppendorf, Hamburg, Germany).  
 
To subgenotype HBV, the following master mix was prepared: 7.5 µl BQW, 2 µl 10X 
Buffer and 0.5 µl of the restriction enzyme StuI (Promega, Madison, WI). 10 µl of this 
reaction mix was dispensed into a 0.5 ml Eppendorff containing 10 µl of the PCR 
product. 1 drop of sterile mineral oil was added to the mixture, and then incubated at 
37ºC for 1 hour on a hot block. The reaction was terminated by the addition of 4 µl 
loading dye. To visualize the restricted bands, 10 µl of the sample was then run on a 3% 
composite agarose gel overnight at ~30V alongside a 100 bp and 1 kb molecular weight 
marker (Promega, Madison, WI, USA).  
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2.10 SEQUENCING OF HBV DNA 
 
The clones containing the correct size amplicons were prepared for sequencing using the 
BigDye Terminator v3.0 Cycle Sequencing Ready Reaction Kit (Applied Biosystems, 
Foster City, USA). Sequencing was carried out on a 377 DNA automated sequencer 
(Applied Biosystems, Inc) using HBV-specific primers (Table 2.6). All sequences were 
analysed in both the forward and reverse directions.   
 
 
 
Table 2.6: Oligonucleotide primers and annealing temperatures for sequencing the 
surface gene of HBV 
       Primer                                         Sequence                                                    Annealing     
                                                                                                                             Temperature 
        116(+)         
                
        521(+)         
 
5’ TATCGTCAATCTTCTCG 3’ 
 
5’ CCTGCACGACTCCTGCTCAA 3’ 
 
5’ CTCCAATTTGTCCTGGTTATC 3’ 
 
5’ CATCATTTTGTGGGTCACCAT 3’ 
 
50°C       
                 
60°C 
                 
50°C 
                
66°C 
         840(+) 
 
       2810(+) 
                  
50°C           T7(+) 5’ GTAATACGACTACTATAGGGC 3’ 
         270(-) 
         455(-) 
       1011(-)     
         898(-) 
5’ AGAGAAGTCCACCACGAGTCTAGA 3’ 55°C        
                 
55°C 
                 
66°C 
                 
50°C 
5’ CAAGGTATGTTGCCCGTTTG 3’ 
5’ CAAAAGACCACAATTCTTTGACATACTTTCCAAT 3’ 
5’ GTCGTGCAGGTTTTGCAG 3’ 
        M13(-)    5’ AGCGGATAACAATTTCACACAGG 3’ 
Abbreviations: (+) sense, (-) anti-sense 
                 
50°C 
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2.11 PHYLOGENETIC ANALYSES 
 
Complete surface gene sequences from the responder, reverter and non-responder were 
compared with corresponding sequences of HBV from GenBank. Multiple sequence 
alignments were carried out using Dambe (Xia, 2000). The alignments were edited 
manually in GeneDoc (Nicholas, 1997) and fed into PHYLIP (Phylogeny inference 
package) version 3.5c (Felsenstein, 1995). DNAML (maximum likelihood) alone and 
DNADIST consecutively with NEIGHBOR (neighbour-joining) were used to generate 
dendograms. SEQBOOT, DNADIST and NEIGHBOR were used for bootstrapping of 
1000 data sets.  CONSENSE was used to compute a consensus tree. Finally, trees were 
visualized using the TreeView Win 32 software program (Page, 1996). 
 
2.12 STATISTICAL ANALYSES 
 
The relevant statistical test, namely one-way ANOVA’s, were used to analyze the 
nucleotide and amino acid divergences between the responder, reverter and non-
responder at the different times of sampling. 
 
2.13 ETHICAL CONSIDERATIONS 
 
The protocol was approved by the Biomedical Research Ethics Committee, Faculty of 
Medicine, Nelson R. Mandela School of Medicine, University of Natal, Reference 
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number: E114/04 (Appendix A2) and informed consent was obtained from the parent or 
guardian for entry into the study. Approval was also obtained by the Human Research 
Ethics Committee, protocol number M050705 (Appendix A1), University of the 
Witwatersrand, for the use of serum samples in the present study. 
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Chapter 3: RESULTS 
 
HBV DNA from a responder, reverter and non-responder were extracted from the serum 
samples obtained from Black children with membranous nephropathy treated with IFN 
for 16 weeks. At 40 weeks of follow up, the responder had cleared HBeAg whereas the 
reverter had cleared HBeAg during treatment but then reverted to being HBeAg-positive. 
The non-responder failed to clear HBeAg. Clearance of HBeAg was associated with the 
appearance of anti-HBe. None of the patients cleared HBsAg. All children had high HBV 
DNA levels on commencement of treatment (>2 x 10 6 genome/ml) (Bhimma et al., 
2002a).  The responder showed a decline in HBV DNA levels at 40 weeks and the levels 
were unchanged in the non-responder. The reverter showed a decline in HBV DNA levels 
at 16 weeks but reverted to pretreatment levels after the cessation of treatment (Bhimma 
et al., 2002a).   
 
Full genome amplification of the non-responder (NON-RESP) and surface gene 
amplification of the responder (RESP) and reverter (REV) was carried out at time points 
before (T0), during (T2 and T4, 4 and 16 weeks after the initiation of treatment, 
respectively) and after treatment (T6, 40 weeks after the initiation of treatment).  
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3.1 DETECTION OF AMPLIFIED PCR PRODUCTS   
3.1.1 Complete Genome Amplification 
 
The method for complete genome amplification of Günther et al (1995) could not be used 
to amplify HBV DNA from the serum of IFN-treated patients and therefore the method 
was modified and adapted. Because the concentration of DNA was found to be too high 
in our samples, the extracted DNA was diluted 1:2 or 1:5 with BQW. Moreover, instead 
of using an annealing temperature of 57ºC, a gradient ranging from 57º to 62ºC was 
applied. Using these modifications, the complete genomes of HBV isolates from the non-
responder were successfully amplified at the various time points, T0, T2, T4 and T6. The 
correct size amplicons were visualized on a 1% agarose gel as a 3.2 kb band (Figure 3.1). 
The optimum amplification was obtained using a dilution of the DNA extract of 1:2 and 
an annealing temperature of either 57º or 60º C. 
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M1   M2    1     2      3     4     5     6      7      8      9    10   11    12    13    14 
   4 kb 
   3 kb 
 
 3.2 kb 
 
 
Figure 3.1: Identification of HBV full-length genomes from a non-responder as seen by a 3.2 kb band 
on a 1% ethidium bromide-stained agarose gel.  M1 = 1 kb molecular weight marker; M2 = 100 bp 
molecular weight marker; Lanes 1, 8, 14 = BQW blank; lanes 2-7 = HBV DNA at a 1:5 dilution 
corresponding to annealing temperatures ranging from 57ºC – 62ºC; lanes 9 – 13 = HBV DNA at a 1:2 
dilution corresponding to annealing temperatures ranging from 57ºC – 61ºC. 
 
Where HBV DNA concentrations were not high enough and full genome amplification 
was not possible, as was the case for the responder and reverter, only the preS1/S2/S-
gene was amplified at T0, T2, T4 and T6 for these samples.  
 
3.1.2 Surface Gene Amplification 
 
In order to optimize the surface gene PCR, amplification was attempted on two different 
machines, the GeneAmp PCR System 9600 Perkin Elmer (Biotechnology, U.S.A) and the 
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Eppendorf Mastercycler® Gradient (Eppendorf, Hamburg, Germany). After amplifying 
the HBV DNA extracted from the serum samples obtained from the responder, at all time 
points, on both machines, it was found that the Perkin Elmer gave better amplification 
and was therefore used for all subsequent experiments. Bands of the appropriate size, 
2119 bp for first round PCR and 1411 bp for second round PCR from the responder and 
the reverter were visualized after electrophoresis on a 1% agarose gel (Figure 3.2).  
 
                    RESP on Perkin Elmer    RESP on Eppendorf 
 
          
         M1  M2  T0  T2   T4   T6       T0  T2   T4   T6           B 
 
 
 
 
 1411 bp  
   
  non-specific 
  bands 
1500 bp 
1000 bp 
 
 
 
 
 
 
 
Figure 3.2: Comparison of second round S-region PCR from a responder after amplification on the 
GeneAmp PCR System 9600 Perkin Elmer (Biotechnology, U.S.A) and Eppendorf Mastercycler® 
Gradient (Eppendorf, Hamburg, Germany).  M1 = 1 kb molecular weight marker; M2 = 100 bp 
molecular weight marker. Amplification of the S region on the Perkin Elmer resulted in the correct size 
amplicons, namely 1411 bp for all time points (T0, T2, T4, T6) whilst amplification on the Eppendorf 
resulted in non-specific binding of the primers. B = BQW blank.  
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All full genome amplicons from the non-responder and surface genes amplicons from the 
responder and reverter, at all time points, were cloned into a pCR-XL-TOPO vector 
(Invitrogen, Carlsbad, CA). 
 
 
3.2 IDENTIFICATION OF POSITIVE CLONES 
3.2.1 EcoRI Digestion 
 
Following TOPO® XL cloning and the extraction of plasmids, samples were digested 
with the restriction enzyme EcoRI (Promega, Madison, WI) to check whether the PCR 
amplicons were inserted correctly into the plasmids. After overnight electrophoresis on 
an ethidium bromide-stained 1% agarose gel, the correct sized amplicons were identified: 
for full-length clones, by a 3.5 kb plasmid band and a 1.8 kb and 1.4 kb band (Figure 3.3) 
and for the surface region, positive clones were visualized by a restriction pattern of  
3.5 kb, 1 kb and 400 bp bands (Figure 3.4).  
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Figure 3.3:  Visualisation of full-length HBV positive clones from a non-responder at T0, after EcoRI 
(Promega, Madison, WI) digestion for 2 hours.  M1 = 1 kb molecular weight marker; M2 = 100 bp 
molecular weight marker; lanes 1-7 = NON-RESP positive clones; B = BQW blank. 
 
4 kb 
 
3 kb 
 
 
 
1 kb 
 
 
  500 bp  400 bp 
3.5 kb 
 
 
 
 
 1 kb 
 
         M1  M2  M3   1   2    3    4     5     6     7     8     9  
 
 
Figure 3.4: Visualisation of HBV surface gene positive clones from a responder at T4. M1 = 1 kb 
molecular weight marker; M2 = 100 bp molecular weight marker; M3 = 50 bp molecular weight marker; 
lane 1= BQW blank; lanes 2-6, 8-9 = positive clones for HBV surface gene; lanes 7 = negative clone not 
containing surface gene.  
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Following the identification of positive clones, the full-length and surface gene clones 
were genotyped and subgenotyped using RFLP analysis.  
 
3.3 GENOTYPING 
3.3.1 RFLP Analysis of Clones 
 
Genotyping of HBV clones relies on the amplification of a region of the S gene of HBV, 
followed by the digestion of amplicons by restriction enzymes and RFLP analysis. 
Nucleotides 256 to 796 of the surface gene of HBV were successfully amplified from the 
full-length and the surface gene clones as shown by the presence of a 541bp band on a 
1% agarose gel (Figure 3.5).  
 
 
 
 
 
 
 
 
600 bp 
500 bp 
541 bp 
                    
    M1 M2   1   2     3    4    5     6    7    8    9   10   11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28   
 
Figure 3.5: Identification of HBV surface gene PCR amplicons for genotyping of a reverter as seen 
by a 541 bp band on a 1% ethidium bromide-stained agarose gel.  M1 = 1 kb molecular weight marker; 
M2 = 100 bp molecular weight marker; Lane 1 = BQW blank; lanes 2-13 and 15-28 = positive PCR 
amplicons; lane 14 = negative for PCR product. 
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The PCR products were then digested using restriction enzymes Hinf I and Tsp 509I. The 
RFLP pattern for all clones corresponded to that for genotype A: 274 bp, 252 bp and 15 
bp fragments for Hinf I and 207 bp, 126 bp, 109 bp, 47 bp and 16 bp fragments for Tsp 
509I (Lindh et al., 1997) (Figure 3.6). Fragments smaller than 40 bp could not be 
visualized on the agarose gel, because of their small size.  
 
 
 
300 bp 
250 bp 
200 bp 
150 bp 
 
100 bp 
   
 50 bp 
 
 
 
 
Figure 3.6: RFLP analysis of S-region amplified HBV clones on a 3% composite gel.  
The resulting pattern is characteristic of genotype A. M1 = 100 bp molecular weight marker; M2 = 50 bp 
molecular weight marker; B = BQW blank. Lanes 1, 3 5, 7, 9 = Hinf I restricted PCR products of RESP T2 
Lanes 2, 4, 6, 8, 10 = Tsp 509I restricted PCR products of RESP T2 
Lanes 11, 13, 15, 17, 19, 21, 24, 25 = Hinf I restricted PCR products of RESP T6 
Lanes 12, 14, 16, 18, 20, 22, 23, 26 = Tsp 509I restricted PCR products of RESP T6 
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3.4 SUBGENOTYPING  
3.4.1 A1 versus A2 
and A2 of genotype A, digestion with StuI 
(Promega, Madison, WI) was carried out following the amplification of a 671bp 
amplicon (nucleotide position 521-1192) (Kew et al., 2005). All genotype A clones were 
enotype A1 as demonstrated by 593 bp and 78 bp bands (Figure 
.7).   
 
To differentiate between subgenotypes A1 
found to belong to subg
3
    M1 M2   1     2     3     4     5    6     7     8    9    10   B 
 
 
 
 
 593 bp 
600 bp 
500 bp 
 
Figure 3.7: Subgenotyping of HBV clones on a 3% composite gel demonstrating the characteristic 
593 bp and 78 bp bands unique to subgenotype A1. M1 = 100 bp molecular weight marker; M2 = 50 bp 
molecular weight; lanes 1-10: NON-RESP (T2) clones 1 -10; B = BQW blank.   
 
  78 bp 
100 bp 
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3.5 DNA SEQUENCING AND ANALYSES 
 
The DNA sequences of the preS1/preS2 and S genes were det  from serum 
samples taken from HBV infected Black children before, during and after IFN treatment 
(Table 3.1) and compared with corresponding sequences of HBV from GenBank. A total 
of 93 seq  of the surface gene of HBV were analysed in this study: 33 clones from a 
responder, 27 clones from a reverter and 33 clones from a non-responder. The alignments 
were edited manually by GeneDoc (Nicholas, 1997).  
          clones 
ermined
uences
 
Table 3.1: Summary of the number of surface gene clones analysed in this study  
Sample         Number of clones analysed for each time point          Total number of     
                           T0                 T2                T4                  T6            
RESP                 10                  10                  5                     8                            33 
     6                            27 
ON-RESP       10                  10                  3                    10                           33 
REV                    9                    8                   4                
N
 
Using the sequences from the clones, the nucleotide/amino acid divergences were 
calculated for each isolate at all time points.   
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3.5.1 Comparison of Mutations in a Responder, Reverter and Non-
responder 
 
In order to compare the HBV population in the responder, reverter and non-responder, 
tilized to 
alculate nucleotide divergences of clones compared to a reference sequence, AY233274 
culated 
ivergences, were expressed as means ± 
andard deviation as a percentage, in order to determine the variation within the samples 
t each time point. Using the GraphPad InStat program, one-way ANOVA’s were 
erformed on the data to test whether mean nucleotide and amino acid divergences 
iffered amongst the responder, reverter and non-responder, and at the various times of 
pling. When p<0.05, the variation was statistically different. The statistically 
significant differences in the nucleotide and amino acid divergences between the various 
case of the responder the only significant difference at the nucleotide and 
amino acid level was in the preS2 region between the time points. The nucleotide 
DAMBE (Data Analysis in Molecular Biology and Evolution) (Xia, 2000) was u
c
(GenBank accession number) (Table 3.2). Amino acid divergences were then cal
(Table 3.3) and together with nucleotide d
st
a
p
d
sam
times of sampling are highlighted in red (Table 3.2 and 3.3).   
 In the 
divergence between T0 and T4 was found to be statistically significant (Table 
3.2), and related to a significant amino acid difference between T4 and all other 
time points (Table 3.3). Clones from T4 displayed the highest amino acid 
divergences. 
 In the reverter a statistically significant difference in nucleotide divergence within 
the entire S gene was observed between T2 and all other time points of sampling 
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(Table 3.2), This was as a direct result of the significant differences in preS1 and 
HBsAg of the reverter (Table 3.2). HBV isolates sampled at T6 displayed the 
highest nucleotide divergence.  However, when the amino acid divergence was 
compared, the significant difference was observed between T4 and all other time 
points of sampling (Table 3.3), with isolates from T4 showing the highest amino 
acid divergence.  The amino acid variation in the entire S region of the reverter 
 
er, this significant difference in HBsAg did not carry through to the 
 
 
 
 
 
 
 
could be accounted for by the significant differences observed in the preS1 and 
preS2 region but not HBsAg.  
Interestingly the nucleotide variation in the case of the non-responder was only 
seen in the highly conserved HBsAg between T6 and all other time points (Table 
3.2), with T6 showing a significantly higher nucleotide divergence than other time 
points. Howev
amino acid divergence indicating that the difference in nucleotide divergence was 
as a result of silent mutations. When looking at amino acid variation, a 
statistically significant difference was observed between time points in the preS1 
region, with variation being the highest at T0 (Table 3.3).  
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Tab  
reverte
Region ue¶  
le 3.2: Mean nucleotide divergence (%) of the entire surface gene for a responder, 
r an non-responder before, during and after IFN treatment 
           Sample     Nucleotide divergence and standard deviation* 
    T[0]                T[2]               T[4]                   T[6] 
    P val
Entire 
           
           
 
reS1            RESP 
                     REV 
               NON-RESP 
reS2            RESP 
                     REV 
               NON-RESP 
                 NON-RESP 
3.81±0.20       4.06±0.15        3.64±0.73         3.85±0.20 
4.08±0.37       2.98±0.21        3.99±0.35         3.83±0.14 
3.05±0.21       2.83±0.38        2.71±0.43         2.83±0.31 
 
2.85±0.29       3.27±0.42        4.24±1.42         3.33±0.92 
5.56±0.20       4.95±0.83        5.03±1.60         5.49±0.39 
4.48±0.42       4.30±0.19        4.24±0.00         4.12±0.85 
        1.17±0.29   
0.19 
31 
 
 
0.1142 
<0.0001 
0.2626 
  
0.0201 
0.3391 
0.5281 
0.3995 
<0.0001 
S         RESP 
            REV 
      NON-RESP 
2.29±0.21       2.45±0.18        2.38±0.13         2.27±0.23 
2.63±0.18       2.13±0.17        2.64±0.37         2.72±0.10 
2.19±0.17       2.04±0.18        2.00±0.17         2.07±0.22 
 
0.2011 
<0.0001
0.2577 
P
  
  
 
P
  
  
 
HBsAg         RESP 
 
1.37±0.40       1.41±0.26        1.26±0.25 
 
                      REV 1.17±0.24       1.01±0.28        1.36±0.18         1.47±
1.17±0.35       1.07±0.23        1.08±0.08         1.77±0.
0.0086 
†Sequences compared to
nces 
i e
 AY233274 (GenBank accession number) 
*Nucleotide diverge ± standard deviations expressed as percentages 
¶ This measures the sign ficant difference between the time points within each pati nt 
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Table 3.3: Mean amino a
ond
at various time points after treatment* 
e¶
cid divergence (%) of the entire surface gene for a responder, 
reverter and non-resp er before, during and after IFN treatment 
Region           Sample          Amino acid divergence and standard deviation 
    T[0]                T[2]                 T[4]                   T[6] 
   P valu
Entire S          RESP 
               NON-RESP 
 
HBsAg          RESP 
                       REV 
P  
.38±0.38       3.23±0.34        3.00±0.00        2.95±0.51 
     2.35±0.35 
    10.36±1.73 
1.28±0.74        1.81±0.73        1.15±0.67        1.16±0.75   
6 
 
.1138 
0.0453 
  
0001 
07 
0.5162 
0.2055 
0.4477 
                       REV 
  
 
PreS1             RESP
                       REV 
 3.03±0.46       3.48±0.59        3.05±0.60        3.06±0.46 
 3.03±0.36       2.91±0.35        3.63±0.32        2.92±0.30 
 3
 
 4.54±0.43       4.87±0.66        4.20±1.33        4.62±0.45 
 3.17±1.09       2.73±0.74        4.83±1.06        3.36±0.00 
 0.2089 
 0.0111 
 0
  
0.3749 
0.0051 
                 NON-RESP  2.86±0.43       2.60±0.48        2.24±0.48   
  
PreS2            RESP 6.72±0.88         7.45±0.58       9.82±1.00       7.50±1.17 <0.
                      REV 
                 NON-RESP 
10.91±0.00      11.37±1.29     12.73±1.48     10.91±1.15 
11.09±1.03      10.91±0.00     10.91±0.00 
0.04
 
                 NON-RES
 
0.98±0.53        0.77±0.31        1.00±0.67        1.18±0.3
1.68±0.58        1.77±0.51        1.62±0.25        2.17±0.57 
  
 0.1762 
†Sequences compared to
s
easures the significant difference between the time points within each patient 
 AY233274 (GenBank accession number) 
*Amino acid divergence  ± standard deviations expressed as percentages. 
¶ This m
 78
Figure 3.8 compares the  
 stra t
 b
etween the responder, everter and non-responder (Figure 3.8A). However, within 
cid e
nt fr B
d
uch lower than that of e responder throughout all the time points. It is also clear from 
 rev
of th a
i
der (blue plot) 
lot) 
 differences in amino acid divergences of the S gene and its 
regions between the ins from the responder, reverter and non-responder.  Wi hin the 
entire surface gene, no significant difference in amino acid divergence was o served 
b r
preS1, the amino a divergence of the strains obtained from the respond r were 
significantly differe om those of the non-responder (p=0.0024) (Figure 3.8 , blue 
versus yellow plot). The amino acid variation within the non-responder was foun  to be 
m th
figure 3.8B, that the erter showed the greatest expansion of quasispecies over time 
compared with that e responder and non-responder, where the population v riation 
remained constant over t me.  
  
In the preS2 region the amino acid variation of the strains from the respon
were significantly lower at all time points compared to the reverter (p<0.01) (pink p
and non-responder (p<0.01) (yellow plot) (Figure 3.8C). Before initiation of treatment 
T0, the non-responder and reverter had a higher amino acid divergence compared with 
that of the responder. The same was true for T2 and T6. However, at T4 the amino acid 
variation within the reverter increased sharply. Overall, the responder showed the lowest 
change in amino acid variation, with the reverter showing the highest variation. The 
population within the non-responder remained relatively constant over time. In both the 
responder and reverter, treatment seemed to be controlling the dominant population but at 
T4, another population emerged, thus contributing to the expansion of the quasiespecies. 
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In the most conserved region, HBsAg, the only significant difference between amino acid 
divergences occurred between strains from the non-responder and reverter at all time 
ints  (p=0.038) (Figure 3.8D). Although amino acid variation stayed relatively constant po
over time for all three patients, it was lower in isolates from the reverter than in the 
isolates from the non-responder at all time points (Figure 3.8D, pink plot versus yellow 
plot).  
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Figure 3.8: Comparison of amino acid divergences (%) over A.) the entire surface gene and B.) 
the preS1 region, for a responder, reverter and non-responder over time. 
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Figure 3.8: Comparison of amino acid divergences (%) over C.) the preS2 region and D.) HBsAg, for 
a responder, reverter and non-responder over time.  
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Figure 3.9 summarizes the results depicted in tables 3.2 and 3.3 and figure 3.8. For all 
patients, at all time points, the most variable region was found to be preS2, while HBsAg 
was the most conserved (Figure 3.9). When comparing the patients, the lowest variance 
within preS2 was seen in the responder with the highest being seen in the reverter (Figure 
3.9). The lowest divergence within HBsAg was observed in the reverter, with the highest 
being in the non-responder (Figure 3.9).  The amino acid divergence of S region as a 
whole, the preS1, preS2 and HBsAg of the strains from the non-responder remained 
constant over time (Figure 3.9C). The amino acid divergence of the responder and 
reverter however, varied between the different time points (Figure 3.9A and B 
respectively) demonstrating the emergence of new populations over the course of therapy.    
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Figure 3.9:  Comparison between amino acid divergences within the regions of the surface gene 
before, during and after IFN treatment. Amino acid divergence for A.) a responder B.) reverter and C.) a 
non-responder.  
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3.5.2 Analysis of Genetic Variability of the Surface Gene 
 
Based on the amino acid composition of the HBsAg deduced from the nucleotide 
sequences, the serological subtypes of the clones of all isolates were determined to be 
adw2 (Table 3.4). One clone sequenced from the reverter at T4 had a Lys160 to Glu160 and 
Phe134 to Ile143 change, which did not however affect the serological subtype. 
 
Table 3.4: Amino acid residues in HBsAg involved in adw2 subtype determination  
Subtype    aa 122        aa 125        aa 127        aa 134        aa 143       aa 159      aa 160        aa 168 
adw2          Lys              Thr             Pro             Phe              Thr            Ala           Lys             Val 
 
Various amino acid changes were observed in the responder, reverter and non-responder 
in comparison to the reference sequence used namely AY233274 (GenBank accession 
number). Only those mutations occurring in either more than two clones or in two or 
more of the isolates will be discussed.   
 
The presence of unique amino acid (aa) residues in the preS1 and preS2 region of HBV, 
characteristic of subgenotype A1, were found in all clones of the non-responder, 
confirming previous subgenotyping RFLP analyses, which showed the non-responder to 
belong to subgenotype A1 (Section 3.4.1). The unique amino acids in the preS1 region 
were: Gln54, Val74, Ala86 and Val91 and in the preS2 region: Leu32.   
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In the responder the most frequently observed mutation in the preS1, was an A-to-T 
transversion at nucleotide (nt) 3009, which resulted in a Gln54 to His54 substitution. 
Interestingly, this mutation, occurring within a subgenotype determinant residue, was 
observed in 100% of clones from T0 and T6 and in 90% and 60% of clones from T2 and 
T4 respectively (Table 3.5) and may account for the fact that the responder showed the 
highest amino acid divergence within preS1, compared with the non-responder and 
reverter at T0, T2 and T6. Another mutation, a Val91 to Phe91, was found in 50% of the T2 
clones from the reverter (Table 3.5). Both the aforementioned amino acid changes were 
not characteristic of any other genotype and are thus unique and do not appear to affect 
the subgenotype of the strains as demonstrated by the fact that the RFLP pattern did not 
change. 
 
Leu32, which has been identified as being characteristic of subgenotype A1 (Kimbi et al., 
2004) was mutated to a His32 in all clones of the responder at all time points and in 50% 
of clones from T2 and T4 of the reverter. Within the major antigenic epitope region of 
preS2, a Gln10 to Lys10 change was found in 100% of the clones from the non-responder 
at T0, T2, and T4 and in 90% of clones from T6 (Table 3.5). A different mutation at this 
position was also observed in strains from the responder and reverter. A Gln10 to Arg10 
substitution was present in 40% of clones from the responder at T4 as well as in 100% of 
T0 and T6 clones, 37.5% of T2 clones and 50% of T4 clones from the reverter (Table 3.5 
and Figure 3.10). Interestingly, in the preS2 region, the amino acid divergence of the 
non-responder remained constant throughout treatment, whereas the amino acid 
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divergence of the responder and reverter varied, becoming especially high at T4. The 
Gln10 to Arg10 mutation may possibly contribute to this trend. 
 
 
                                                                                                                   A18G 
                                             
Figure 3.10: A chromatogram demonstrating the Gln10 to Arg10 mutation found in the responder and 
reverter as a result of an A-to-G substitution at nt 18 of the preS2 region. 
 
Variation in the amino acid sequence was found throughout the small envelope protein 
(Figure 3.11). A Met1 to Val1 substitution was seen in 20% of clones from the responder 
at T0 and a Met1 to Thr1 mutation was observed in 10% of clones from the non-responder 
at T2 (Table 3.5). Both these mutations occurred within the ATG start codon and would 
probably affect the synthesis of the HBsAg.  
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Two sets of mutations were detected just upstream of helix I of HBsAg, on the outside of 
the ER membrane. A Glu2 to Gly2 substitution, was found in 50% of clones from the 
reverter at T2 and a Phe8 to Ser8 change in 20% of clones from the responder at T2 and in 
10% of clones from the non-responder at T0 (Table 3.5). Within 50% of clones from the 
reverter at T2, a Leu13 to Phe13 mutation was found in helix I of HBsAg (aa 11-29), which 
crosses the ER membrane and translocates the upstream sequence into the ER lumen 
(Table 3.5). In the major cytoplasmic loop of HBsAg, two mutations were detected in the 
non-responder: a Leu49 to Arg49 in 8 clones; 20% of clones from T2 and 60% from T6 
and Leu77 to Arg77 substitution occurred in 20% of clones from T0 and 10% of clones 
from T2 (Table 3.5).    
 
Mutations were also present within the second helix of HBsAg corresponding to the 
immunodominant region (aa 101-168) or major hydrophilic region (MHR). A Met103 to 
Ile103 substitution was present in the 25% of T4 clones and 50% of T6 clones from the 
reverter (Table 3.5).  Downstream of this, a Gly112 to a Arg112 mutation occurred in 3 
clones from the reverter; two from T2 (25%) and one from T4 (25%) and in five clones 
from the non-responder; four from T2 (40%) and one from T4 (33%) (Table 3.5).  
 
The clones from the responder and reverter both contained mutations in the major 
antigenic determinant of HBsAg, the ‘a’ determinant (aa 124 to 147), thus possibly 
having a pronounced effect on antigenicity. A Gln129 was substituted for an Arg129 in one 
clone from each time point, T0 (11%), T2 (12.5%) and T6 (17%) of the reverter (Table 
3.5). Further down, a Met133 to a Thr133 mutation was seen in 25% of clones from the 
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reverter at T4 and occurred in 40% of T0, 50% of T2, 60% of T4 and 50% of T6 clones 
from the responder (Table 3.5). Still within the ‘a’ determinant, a Asp144 to Gly144 
mutation, found in the responder at all time points and a Asp144 to Ala144 occurring in one 
clone of the non-responder at T4, was found as a result of a A-to-G or a A-to-C transition 
at nt 585 (Table 3.5). A Glu164 to Gly164 substitution was present in 20% of clones at T0, 
50% of clones at T2 and 12.5% of clones at T6 of the responder as well as in 33% of 
clones from T0 and in 17% of clones from T6, of the reverter (Table 3.5).   
 
Two further mutations were identified. A G-to-A transition at nt 700 led to a Trp being 
substituted for a stop codon at aa 182 in the non-responding patient in 10% of clones 
from T0, 20% of clones from T2 and 67% of clones from T4 (Table 3.5). This mutation 
would possibly lead to a truncated HBsAg protein and have a pronounced effect on 
patient response. Also, in the responder, a Leu186 was substituted for a Pro186 in 20% of 
T0 and T2 and 37.5% of T6 clones (Table 3.5).  Although these mutations were found 
outside of the major antigenic determinant downstream of helix II, they could 
nevertheless still affect antigenicity. 
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Table 3.5: Summary of unique mutations present within the surface gene of IFN-treated 
patients 
 
HBV          Nucleotide*    Amino acid       Sample          Number of clones       % of  
Region       Substitution     Substitution                                  with                   clones 
                                                                                          mutation                with 
                                                                                                                            mutation                               
 
PreS1  A3009T Q54H  RESP   29/33  88%  
  G3118T V91F  REV   2/27  7% 
 
PreS2  C17A  Q10K  NON-RESP  32/33  97% 
  A10G  Q10R  REV   20/27  74% 
      RESP   2/33  6% 
 
HBsAg A155G M1V  RESP   2/33  6% 
  T156C  M1T  NON-RESP  1/33  3% 
  A159G E2G  REV   4/27  15% 
  T177C  F8S  NON-RESP  1/33  3% 
      RESP   2/33  6% 
  C191T  L13F  REV   4/27  15% 
  T300G  L49R  NON-RESP  8/33  24% 
  T384G  L77R  NON-RESP  3/33  9% 
  G463C  M103I  REV   4/27  15% 
  G488A G112R  NON-RESP  5/33  15% 
      REV   3/27  11% 
  A540G Q129R  REV   3/27  11% 
  T552C  M133T REV   1/27  4% 
      RESP   16/33  48% 
  A585C  D144A NON-RESP  1/33  3% 
  A585G D144G RESP   15/33  45% 
  A645G E164G  REV   4/27  15% 
      RESP   8/33  24% 
  G700A W182STOP NON-RESP  5/33  15% 
  T711C  L186P  RESP   7/33  21%  
 
 
* Sequences compared to AY233274 (GenBank accession number), where position 1 
corresponds to the EcoRI cleavage site. 
 
 
 90
  
 
L49R 
W182STOP  
 
   L186P 
F8S
 E2G    M1V/T
 E164G
   D144A/G 
  M133T
 Q129R
G112R 
L77R 
M103
L13F 
COOH
107
  
  I 
  
  II 
 
 IV 
 
  V 
 ‘a’ determinant 
137
149
121 124
138
139
147
NH2 
 
 III
Cytoplasm 
 
Figure 3.11: Graphic representation of mutations found within the small envelope protein of the 
responder, reverter and non-responder clones.  
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3.6 PHYLOGENETIC ANALYSIS 
 
DNADIST was used consecutively with NEIGHBOR (neighbour-joining) to generate 
dendograms of all surface gene clones from the responder, reverter and non-responder at 
all time points. Trees were then visualized using TreeView Win 32 software program 
(Page, 1996) together with isolates corresponding to all genotypes from GenBank in 
order to access the genotype distribution of these samples. Analysis of samples showed 
the clustering of the responder, reverter and non-responder with genotype A1, confirming 
previous analysis.  There was no separation of the strains in each patient according to 
time of sampling showing that within each patient there was a mixed population. 
 
Figure 3.12 demonstrates the phylogenetic trees visualized using TreeView Win 32 
software program (Page, 1996) for the responder, reverter and non-responder at the 
different times of sampling: 
 At T0, the patients form distinct clusters, with strains from each patient clustering 
together. The strains of the reverter and non-responder were the most similar 
sharing the same root and clustering together.  
 At T2, the responder and the non-responder keep the same cluster as at T0, 
showing that the population remains the same in these patients. However, the 
reverter separates into two clusters with separate roots, demonstrating the 
emergence of an additional population. 
 At T4, the responder clustered into two distinct populations. Within the strains of 
the reverter, a completely new population emerged as shown by the two distinct 
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clusters, even more separate from those at T2. In the non-responder, a new 
population also emerged distinct from that at T0 and T2.   
 At T6, the new populations within the responder, reverter and non-responder were 
knocked out causing the original populations present at T0 to re-emerge, 
regardless of whether the patients were a responder, reverter or non-responder.     
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Figure 3.12: Phylogenetic tree comparing the complete S ORF of the responder, reverter and non-
responder at A.) T0 and B.) T2 to other genotype A HBV isolates obtained from GenBank 
(designated by its accession number) established using neighbor-joining. Bootstrap statistical analysis 
was performed using 1 000 data sets and the numbers on the nodes indicate the percentage of occurences.   
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Figure 3.12: Phylogenetic tree comparing the complete S ORF of the responder, reverter and non-
responder at C.) T4 and D.) T6 to other genotype A HBV isolates obtained from GenBank 
(designated by its accession number) established using neighbor-joining. Bootstrap statistical analysis 
was performed using 1 000 data sets and the numbers on the nodes indicate the percentage of occurences.   
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 Chapter 4: DISCUSSION 
 
A number of drugs have been used in the treatment of HBV infection, including 
interferon. The response to IFN is usually measured by HBe seroconversion, reduction of 
viraemia, alanine aminotransferase levels and histological examination (Lindh, 1997).  
The ability of IFN to enhance the rate of viral clearance, leading to loss of HBeAg, 
however, only extends to 30-40% of treated patients. The reason for this is unclear. Viral 
sequence heterogeneity may be an important predictor of IFN response.  Although a 
number of studies have been carried out to determine the influence of viral sequence 
heterogeneity on IFN response (Takeda et al., 1990; Zampino et al., 2002; Chen et al., 
2003), none have been within the South African context. Considering that the majority of 
South African HBV isolates belong to subgenotype A1 and have unique sequence 
characteristics (Kimbi et al., 2004), studies on patient response from other countries 
cannot necessarily be directly extrapolated to studies on South African patients. 
Moreover, the genotype of the virus can have important implications in the development 
of mutations and response to therapy (Kramvis and Kew, 2005).  
 
After analysis of the catalytic domains of the polymerase gene, the BCP and precore and 
core regions of HBV following IFN treatment, Chen et al (2003) concluded that the basis 
of non-response or relapse did not lie in these regions and thus must reside in other parts 
of the HBV genome. The surface gene may therefore be a suitable candidate for 
predicting patient response to IFN. Not only does the pre-S sequence contain the highest 
heterogeneity over the entire genome (Lauder et al., 1993; Günther et al., 1999), but the 
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 preS2 region in particular, is known to be hypervariable (Huy et al., 2003). The ability to 
predict response to IFN would have profound implications in the prognostic and 
therapeutic arena.  Therefore, the aim of the present study was to determine whether the 
sequence of preS1/preS2/S region could be used as a predictive factor for IFN response in 
southern African Black carriers of the virus.   
 
Sequencing of the various open reading frames of HBV from subgenomic amplicons does 
not allow the analysis of the mutations present in a single molecule of the complete HBV 
genome (Günther et al., 1995).  Therefore, in this study, we attempted to amplify the 
complete genome of HBV isolates from a responder, reverter and non-responder, at 
various times post-treatment.  This complete genome, however, could only be amplified 
when the HBV DNA levels were high as was the case before treatment for all patients, at 
all time points for the non-responder and when the levels of HBV were at pretreatment 
levels in the case of the reverter.  Therefore we used subgenomic PCR of the complete S 
ORF for the responder and reverter.   
 
In infected individuals, HBV exists as a whole population of phylogenetically related 
variants or quasispecies (Smith et al., 1997), with one strain dominating.  In order to 
maintain the stability of the pool, certain selection pressures from the host’s immune 
system, constraints imposed upon by the reading frames, and the viability and replication 
competence of the virus need to remain intact (Locarnini et al., 2003). Thus the 
interaction between viral and host factors as well as external pressures define the 
dominant HBV population (Locarnini et al., 2003). However, with the introduction of 
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 IFN treatment, the balance may be disrupted, leading to the emergence of mutant HBV 
strains or genotypes able to withstand therapy and consequently causing a non-responsive 
outcome. In order to identify these minority strains or genotypes, the amplicons were 
cloned and the clones genotyped/subgenotyped and sequenced.   
 
The genotype of HBV has been shown to influence the response to IFN therapy (Kramvis 
and Kew, 2005) and when patients treated with interferon contain genotype mixtures 
(Hannoun et al., 2002b), genotype switches can occur (Gerner et al., 1998).  Genotypes A 
and D have been shown to occur in the southern African Black population (Bowyer et al., 
1997; Kimbi et al., 2004), with the unique segment of genotype A, subgenotype A1 
predominating (Kimbi et al., 2004).  To determine whether the genotype/subgenotype 
may influence response to IFN treatment, the clones of the HBV isolates were 
genotyped/subgenotyped.  All HBV clones, at all time points, regardless of IFN response 
of the patient, belonged to subgenotype A1 of genotype A as shown using RFLP analysis 
(Figures 3.6 and 3.7) and had the distinctive sequence characteristics of this 
subgenotype. All isolates had serological subtype of adw2. Therefore differences in 
response to IFN treatment were not as a consequence of genotype or serotype diversity of 
the HBV isolates obtained from the different patients.   
 
The next step was to sequence the preS1/preS2/S region of the clones of the isolates, to 
establish whether sequence heterogeneity in this region of the HBV genome could 
account for differences in the response to IFN treatment. Quasispecies have been 
implicated in failure of vaccines and therapies (Domingo, 1998) and in the incorrect 
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 diagnosis of infectious diseases caused by viruses such as HIV (Brenner et al., 2002) and 
HCV (Gonzalez-Peralta et al., 1996) that are characterized by error prone replication. 
Although HBV is not a RNA virus, it replicates by reverse transcription of the 
pregenomic RNA using a polymerase that lacks proofreading ability and thus sequence 
heterogeneity and the evolution of a quasispecies is also a feature of this virus  
(Steinhauer and Holland, 1986).   
 
When determining sequence heterogeneity, it is important, as cautioned by Smith and 
coworkers (1997), to minimize the number of artefactual substitutions introduced by PCR 
amplification of the virus sequences (Smith et al., 1997).  To do this, in the present study, 
we took the following precautions: 
 We used Expand High Fidelity Enzyme mix that combines Taq DNA polymerase, 
a high amplification efficiency enzyme, with Tgo DNA polymerase, a 
thermostable enzyme with a low error rate and proofreading activity.  
 Because of the high concentration of HBV DNA following serum extraction in 
some samples, the DNA extracts were diluted to 1:2 or 1:5 in order to achieve 
efficient amplification and to prevent the saturation point of amplification being 
reached early and leading to the incorporation of artefactual mutations.    
 The annealing temperature for amplification was optimized for each individual 
sample in order to minimize mispriming. Although Günther utilized an annealing 
temperature of 60ºC, in this study annealing temperatures of either 57º or 60ºC at 
a 1:2 dilution were found to be the most effective for full genome amplification.    
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  In order to differentiate between artefactual and genuine substitutions, sporadic 
substitutions (i.e. occurring in only one of the multiple clones sequenced) were 
not taken into account when calculating nucleotide divergences.   
 Moreover, from the sequences of the S ORF of the clones the nucleotide 
divergences were calculated (Table 3.2) and the error rate per nucleotide per PCR 
cycle was calculated to be between 2.5 and 3.4 x 10-4, which is much higher than 
the expected error rate of  Taq polymerase (0.2 – 2 x 10-4) (Smith et al., 1997).   
 
When summarizing the results obtained for amino acid divergences over all the regions 
of the S ORF for the different patients (Figure 3.9), in agreement with other studies  
(Bowyer and Sim, 2000; Lauder et al., 1993), it was clear that the preS2 region was the 
most variable for all patients and HBsAg was the most conserved. This is to be expected 
because the preS2 protein is not essential for HBV replication, virion morphogenesis, or 
secretion, and is not required for infectivity (Fernholz et al., 1993) whereas HBsAg has 
an essential role in the viral life cycle (Bruss and Ganem, 1991). However, because of the 
importance of the preS region in immunity and protection (D’Mello et al., 1997), the high 
viral variation in this region in the HBV strains isolated from all patients, may have an 
important effect on IFN response. The highest divergence in preS2 was seen in the 
reverter and non-responder, with the highest divergence in HBsAg being seen in the non-
responder (Figure 3.9C). Again, this seems to highlight the fact that the high amino acid 
divergence in these regions may be as a result of certain mutations responsible for 
persistence of the virus and the absence of response to IFN.  The significant increase in 
the amino acid divergence in the preS2 and HBsAg in the non-responsive patients 
 100
 compared with that of the responder could indicate that mutations in these regions may 
carry predictive markers of non-response. Further investigation is therefore warranted.  
  
Phylogenetic analysis of the clones confirmed the results of the RFLP analysis which 
showed all clones of HBV from all patients to cluster with subgenotype A1 within 
genotype A. Moreover, the trees (Figure 3.12) confirmed the relationships and population 
dynamics between the responder, reverter and non-responder reflected by the nucleotide 
(Table 3.2) and amino acid (Table 3.3) variations. When looking at the phylogenetic 
relationship between the patients at each time point, we see that at T0, the strains of each 
patient group together under distinct clusters, with the reverter and non-responder being 
genetically the most similar (Figure 3.12A). However, at T2 (Figure 3.12B), we see the 
separation of the strains within the reverter into two clusters, showing the breakthrough 
of a new population separate from the initial viral strains present at T0. IFN treatment 
therefore seems to be altering the balance within the HBV quasispecies pool and 
selecting for a mutant population able to withstand the treatment. The strains within the 
responder and non-responder remained the same as those at T0. Thus, the onset of 
quasispecies evolution was delayed in these patients. At T4 (Figure 3.12C), the responder 
showed two completely distinct clusters from those seen at T0 and T2 demonstrating the 
expansion of the quasispecies. The reverter showed further separation of its two distinct 
clusters, which was as a result of the expansion of the two populations seen at T2. 
Although the strains of the non-responder remained together, as a whole they clustered 
differently to the populations at T0 and T2. Thus, all three patients seem to demonstrate a 
heterogeneous population, able to mould itself according the selective pressure applied by 
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 the immune system as a result of IFN therapy. IFN treatment is known to increase the 
host immune elimination pressure on HBV-infected cells and to result in the selection of 
HBV quasispecies (Chen et al., 2003). At T6 (Figure 3.12D), there was a reforming of 
the initial clusters in all patients, and thus a reversion to the initial major variant present 
at T0. Hence, in the patients, although there was accelerated quasispecies evolution 
during IFN treatment, the newly emerged populations disappeared at T6 after the removal 
of IFN, causing the clusters to regroup into the original strains found at T0.  
 
In the responder, the most common preS1 mutation, occurring within a subgenotype 
determinant residue, was a Gln54 to a His54 substitution in 100% of T0, 90% of T2, 60% 
of T4 and 100% of T6 clones. This mutation was found in the original cluster of HBV 
isolated from the responder. Not characteristic of any other genotype (Kimbi et al., 
2004), this mutation appears to be unique. Replacing glutamine, a polar amide with high 
flexibility with histidine, a polar, positively charged amino acid containing an imidazole 
ring, would not only change the flexibility of the protein at this point but also potentially 
alter the hydrophobicity of the amino acid. This mutation would possibly have an effect 
on the antigenicity of the protein and may differentiate the HBV isolates from the patient 
responding to IFN treatment from the non-responders.  This mutation has been described 
in asymptomatic carriers with low viral loads (Xu et al., 2006) 
 
Another unique mutation within a subgenotype determinant residue of preS1 occurred in 
two clones from T2 of the reverter. Substitution of a Val91, a non-polar, hydrophobic 
unreactive amino acid for a Phe91 that, although also hydrophobic, is a globular amino 
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 acid, would likely alter the tertiary structure of the preS1 region. As amino acids 81-108 
of preS1 code for the T-cell epitopes and are therefore highly immunogenic (Chisari and 
Ferrari, 1995), a mutation of this nature would likely change the antigenicity of this 
region leading to failure of the T-cells to bind and neutralize HBV. However, as this 
mutation was only present at T2 of the reverter, it is unlikely that it had an effect and it 
was probably eliminated by IFN. 
 
Although the preS2 region of HBV is hypervariable, mutations in this domain may 
modify the course of HBV infection (Huy et al., 2003). A Leu to His substitution at 
amino acid 32 of preS2 was found in 50% of clones from T2 and T4 of the reverter. 
Amino acid 32 is a unique subgenotype determinant of subgenotype A1 (Kimbi et al., 
2004) and in the majority of isolates is characterized by a leucine. However, small 
minorities of A1 isolates contain a His32. Thus, this mutation did not affect the 
subgenotype of the reverter, which was concluded to be A1 (Kimbi et al., 2004).  
 
Within the major antigenic epitope region of preS2, known to carry numerous B-cell, T- 
helper cell and CTL epitopes (Sominskaya et al., 2002), a Gln10 to Lys10 substitution was 
found in 100% of clones from the non-responder at T0, T2 and T4 and in 90% of clones 
from T6. Similarly, a Gln10 to Arg10 mutation (Figure 3.10) was present in 40% of T4 
clones from the responder and 100% of T0 and T6, 37.5% of T2 and 50% of T6 clones 
from the reverter. Glutamine, an uncharged amino acid being replaced by a lysine or an 
arginine, both positive polar amino acids, would likely affect the tertiary structure of the 
epitope. Arginine especially, is capable of intense molecular interactions due to a unique 
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 moiety terminating its side chain, a guanidine group. Given that both these mutations lie 
within a T helper cell epitope region (amino acids 1-15), (Ong et al., 2005), altering the 
structure of this epitope would greatly affect the binding of the T-cells. As the Gln10 to 
Arg10 and Gln10 to Lys10 mutations were found throughout all time points of the reverter 
and non-responder, these mutations may be reducing the ability of the IFN-induced 
antibodies to bind to the epitopes and initiate their neutralizing effect (Wallace et al., 
1997). Thus, the mutation may be providing a survival advantage within the IFN 
environment leading to non-response in these patients. The presence of this mutation may 
be playing a significant role in patient response to IFN and could potentially be used as a 
predictive marker for treatment outcome. 
 
Within the ATG start codon of the HBsAg, a Met1 to Val1 mutation was observed in 20% 
of clones from the responder at T0 while the non-responder possessed a Met1 to Thr1 
mutation in 10% of clones from T2. Both mutations appeared to be in the minority 
population at the start of treatment and were eliminated by T4, intimating that their 
inability to code for complete HBsAg may be a disadvantage to the survival of the 
strains.   
 
Situated between helix I and II, within the cytoplasmic loop, two mutations were detected 
in the non-responder; a Leu49 to Arg49 mutation and a Leu77 to Arg77 mutation. Both 
would lead to a non-polar, unreactive, hydrophobic amino acid being substituted for a 
polar, positively charged, hydrophilic amino acid. Biochemically, this would more than 
likely affect the tertiary structure of the major cytoplasmic loop. However, with the case 
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 of Leu77 to Arg77, this seems improbable, as this mutation was only present in 20% of 
clones from T0 and 10% of clones from T2, showing a decrease in this mutation over 
time. With regards to the Leu49 to Arg49 mutation, it was present at the beginning of 
treatment at T2, in 20% of clones, disappeared at T4 and then reemerged at T6 in 60% of 
clones from the non-responder. Thus, it seems that the immune pressure applied by IFN 
was selecting for this mutant strain, possibly because it was resistant to treatment. As 
amino acids 29-80 of the cytoplasmic loop are involved in the interaction of the core 
particles with the envelope protein (Khan et al., 2004), a mutation in this region may also 
affect the encapsidation of the core particles after virion formation.  
 
The MHR of HBsAg spanning amino acids 101 to 168, is orientated on the surface of the 
virus. 25% of T4 clones and 50% of T6 clones from the reverter possessed a Met103 to 
Ile103 mutation. Given the similar nature of these amino acids, both non-polar, unreactive 
and hydrophobic, the effect on the tertiary structure of the protein at this point seems 
insignificant. However, a Gly112 to Arg112 amino acid substitution would cause a non-
polar, hydrophobic amino acid to be substituted for a polar, hydrophilic amino acid. 
Given the importance of this region and the fact that glycine is a very flexible amino acid, 
this mutation may not only affect the structural integrity of the protein, but may also 
affect the entire immunodominant region. Occurring in clones of the reverter and non-
responder at T2 and T4, this mutation probably developed as a result of this highly 
immunogenic region being under selective pressure from the immune system (Mimms, 
1995) and consequently may be playing a role in the establishment of resistance to IFN.  
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 The major antigenic determinant of HBsAg, the ‘a’ determinant, spans amino acids 124-
147 within the MHR (Figure 3.11) and plays an essential role in antigenicity. A 
commonly occurring vaccine-escape mutant, namely a Gln129 to His129, has been found in 
this region (Wallace et al., 1997). A variation of this mutation corresponding to a Gln129 
to Arg129 substitution was found in the reverter in one clone each from T0, T2 and T6, 
leading to a non-polar, hydrophobic amino acid being replaced by a polar hydrophilic 
amino acid. Khattab et al (2005) also found this mutation in the ‘a’ determinant of occult 
HBV in patients undergoing IFN therapy. A mutation in this region may significantly 
alter the conformation of the epitope thus affecting the binding of the hepatitis B surface 
antibodies (anti-HB’s) to the ‘a’ determinant and reducing the antigenic effect (Khattab et 
al., 2005).  
 
Also within the ‘a’ determinant, 40% of T0 clones, 50% of T2 clones, 60% of T4 clones 
and 50% of T6 clones from the responder and 25% of the clones at T4 of the reverter 
possessed a Met133 to Thr133 point mutation. This led to a non-polar, hydrophobic amino 
acid being replaced by a polar, hydrophilic one, not only having an effect on the tertiary 
structure of the protein, but also affecting the hydrophibicity. Functional studies have 
shown enhanced HBsAg secretion and virion secretion associated with this mutation 
(Khan et al., 2004). Therefore the increased “fitness” may explain the survival and 
persistence of HBV in both the responder and reverter following IFN treatment.   
 
Another commonly described vaccine escape mutant, Asp144 to an Ala144 (Wallace et al., 
1997) occurred in one clone from the non-responder at T4. Even though this mutant is 
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 known to evade the neutralizing effect of antibodies because of reduced antibody binding 
activity (Torresi, 2002), it is unlikely that it had any effect in this patient since it occurred 
at such low levels.  Another mutation, Asp144 to Gly144, which may represent a novel 
vaccine-escape mutant, occurred in the responder at all time points; 40% of T0 clones, 
50% of T2 clones, 20% of T4 clones and 62.5% of T6 clones. 
 
Lamivudine escape mutants such as Glu164 to Asp164/Ile195 to Met195, commonly occur as 
a result of mutations in the ‘a’ determinant, and may have the potential to become 
vaccine escape mutants (Torresi, 2002). A different mutation, namely a Glu164 to Gly164 
mutation was present in 20% of clones from T0, 50% of clones from T2 and 12.5% of 
clones from T6 of the responder as well as in 33% of clones from T0 and 17% of clones 
from T6 of the reverter. Both the Asp144 to Gly144 and the Glu164 to Gly164 mutations may 
interfere with recognition of HBsAg by antibodies, therefore showing reduced binding to 
anti-HB antibodies and could thus represent novel mutations, which have the potential to 
become vaccine escape mutants.  
 
Mutations occurring in the immunodominant epitope for B-cell recognition (amino acids 
178-186), may be caused by negative selection induced by the immune response (Ong et 
al., 2005). Two mutations occurred within this epitope region. Firstly, a Trp182 was 
substituted for a stop codon in 10% of T0, 20% of T2 and 67% of T4 clones from the 
non-responder. In this patient, IFN seemed to be selecting for mutants capable of evading 
the immune response, thus resulting in an increase in this mutation over time.  
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 Secondly, in the responder, a Leu186 to Pro186 mutation occurred in 20% of clones from 
T0 and T2 and in 37.5% of clones from T6. Leu186 is essential for the reactivity of the 
epitope (Paulij et al., 1999) thus substituting it for a proline would possibly alter the 
structure of the epitope, thus affecting the binding of the B-cells. Leucine, a non- polar, 
unreactive, hydrophobic amino acid and proline a non-polar, cyclic amino acid are 
chemically very different. However, because this mutation was present in the responder 
at the start and end of treatment, perhaps it does not inhibit B-cell binding but instead 
enhances it, thus contributing to the increased clearance of HBV-infected cells. This 
mutation may therefore be detrimental to the virus. Clearly, further studies would be 
needed to elucidate the exact role, if any, of this mutation on IFN response.    
 
From phylogenetic analysis of the patients at the different times of sampling, it would 
seem that when an external factor such as IFN therapy is introduced into a system, it may 
disrupt the balance within that system, thus allowing the loss of original viral strain and 
the subsequent takeover by a minor population from the quasispecies pool. The reason for 
this may be that the major population is more susceptible to IFN than the minor strains, 
thus allowing IFN to enhance the immune response toward the major strain and 
subsequently causing the levels of the minor strain to increase (Hannoun et al., 2002b). 
However, when the pressure is removed, as was the case at T6, 40 weeks after the initial 
onset of treatment, the original viral population re-emerges.  
 
When this phylogenetic data is related to the mutations found within the patients, we see 
the presence of certain mutations in the responder that may represent IFN treatment 
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 escape mutants. Gln54 to His54 in the preS1 at all time points, Met133 to Thr133 and Asp144 
to Gly144 at all time points as well as Glu164 to Gly164 and Leu186 to Pro186 at T0, T2 and 
T6 of HBsAg- which may represent the dominant HBV population within this patient. At 
T4, with the separation into three distinct clusters, we also see the decrease of the Gln54 to 
His54 mutation in preS1, the emergence of a Gln10 to Arg10 mutation in preS2 and as 
already noted, the disappearance of the Glu164 to Gly164 and Leu186 to Pro186 mutations in 
HBsAg. This variation in amino acids at T4 may therefore account for the emergence of 
new viral populations.  
 
In the reverter, it would seem that the Gln10 to Arg10 mutation in preS2, present at all the 
time points and Gln129 to Arg129 mutation in HBsAg present at T0, T2 and T6, represent 
the dominant population in this patient. At T2, there was a separation of the strains into 
two clusters and we see the emergence of a Gly112 to Arg112 mutation, which may be 
responsible for the separation into two clusters. At T4 there was a further splitting of the 
populations, and the emergence of the Met133 to Thr133 mutation, also found in the 
responder, thus explaining why these HBV isolates seem to cluster together at T4.  
 
In the non-responder, the Gln10 to Lys10 mutation in preS2 was present throughout all 
time points and represents the dominant population. The Gly112 to Arg112 mutation, also 
found in the reverter, may be responsible for the clustering together of the HBV isolates 
from these patients at T4.  
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 Chapter 5: CONCLUSION 
 
As all strains from the responder, reverter and non-responder were infected with 
subgenotype A1/serological subtype adw2, genotype/serotype differences could not 
account for differences in response between the patients. There were no differences in 
amino acid divergences of the complete S ORF or the HBsAg alone between the HBV 
isolates from the responder, reverter and non-responder. The preS1 region of the 
responder showed the highest amino acid divergence compared to the non-
responder/reverter. On the other hand, the most variable region, the preS2 was least 
conserved in the non-responder and reverter at all time points and therefore a more 
conserved preS2 may represent a predictive factor for response to IFN therapy. The 
responder strains cluster separately from the non-responder/reverter strains at T0. In the 
responder we see the persistence of a HBV strain that may have IFN treatment “escape” 
mutations.  In the reverter we see the emergence of a new population of virus that clusters 
in the same branch as the responder strains at times T2 and T4.  A new strain that clusters 
with the isolates from the non-responder was also seen to emerge in the responder at T4, 
with the original strains re-emerging after the termination treatment in all patients. 
Contrary to observations of other limited studies on different genotypes (Liu et al., 2004), 
in the present study we see that the viral population dynamics differ between the 
responder strains and the non-responder/reverter strains. Further research with more cases 
and functional studies, such as the approach used by Wang et al (2005), are therefore 
needed to determine whether these observations are pertinent only to this pilot study or 
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 may be more generalized phenomenon that may provide us with a predictive tool for IFN 
treatment of patients infected with subgenotype A1 isolates of HBV.   
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Appendix D: SOLUTIONS, CHEMICALS AND REAGENTS 
 
D1. Solutions 
 
0.8% Agarose Gel – Crystal Violet 
 0.4 g Molecular Grade Agarose  
 50 ml 1X TAE Buffer 
o Heat in microwave for approximately 3 minutes or until agarose is 
dissolved; 
o Cool to ~ 55º C; 
o Add 45 µl of 2 mg/ml crystal violet and swirl to mix; 
o Pour into gel tray with comb and allow to set. 
 
1% Agarose Gel – Ethidium Bromide 
 1,5 g Molecular Grade Agarose        
 150 ml 1X TBE Buffer 
o Heat in microwave for approximately 3 minutes or until agarose is 
completely dissolved; 
o Cool to ~ 55º C; 
o Add 20 µl ethidium bromide and mix; 
o Pour into gel tray with comb and allow to set. 
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3% Composite Agarose Gel – Ethidium Bromide 
 6 g NuSieve GTG Agarose           
 3 g Molecular Grade Agarose 
  300ml 1X TBE Buffer 
o Heat in microwave for approximately 5 minutes or until boiling, stirring 
occasionally; 
o Cool to ~ 55º C;  
o Add 30 µl ethidium bromide and mix; 
o Pour into gel tray with comb and allow to set. 
 
Bromophenol Blue Loading Dye 
 0.01 g  Bromophenol blue 
 2 ml  0.2 M EDTA 
                            - 0.4 ml EDTA 
                            - 1.6 ml BQW 
 5 ml  50% glycerol 
                            - 2.5 ml glycerol 
                            - 2.5 ml BQW 
o Make up to 10 ml with distilled water and mix; 
o Aliquot into 1.5 ml microcentrifuge tubes; 
o Store at 4ºC.  
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Ethidium Bromide Stock (10 mg/ml) 
 0.1 g Ethidium Bromide          
 10 ml Best quality water 
o Mix well; 
o Store in a dark bottle at 4º C. 
 
Kanamycin Stock 
 0,5 g  Kanamycin            
o Make up to 10 ml with Best Quality Water; 
o Shake well to mix; 
o Filter sterilize; 
o Aliquot into 1.5 ml microcentrifuge tubes; 
o Store at 4º C. 
 
Luria-Bertani (LB) Medium 
 10 g Tryptone 
 5 g Yeast Extract 
 10 g  Sodium Chloride 
o Make up to 1 L with distilled water and stir; 
o Autoclave; 
o Store at 4º C. 
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Luria-Bertani (LB) agar plates with Kanamycin  
 10 g Tryptone 
 5 g Yeast extract 
 10 g Sodium chloride 
 20 g Bacteriological agar 
o Make up to 1 L with distilled water and stir; 
o Autoclave; 
o Cool to ~ 55º C; 
o Add 1 ml of 50 µg/ml of kanamycin antibiotic; 
o Pour into plates; 
o Allow to set, invert plates and then store at 4º C. 
 
TAE Buffer (10X) 
 24,2 g   Tris-base 
 5,68 ml  Glacial acetic acid 
 10 ml   0.5 M EDTA (pH 8) 
o Make up to 1L distilled water; 
o Autoclave; 
o Store at room temperature. 
 
 
 
 
 145
TBE Buffer (10X) 
 108 g Tris-base 
 9.3 g EDTA 
 55 g Boric acid 
o Make up to 1L with distilled water; 
o Autoclave; 
o Store at room temperature.  
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D2. Chemicals and Reagents 
 
All chemicals and reagents used for this project as well as their sources are listed in Table 
A1 below.  
 
Table A1: Chemicals and Reagents 
Chemicals and Reagents Manufacturers 
Acetic acid glacial Associated Chemical Enterprises 
Bacteriological agar (European 
formulation) 
Whitehead Scientific 
Boric acid Sigma 
Bromophenol blue Merck 
Ethanol (99.7 – 100%) Saarchem, Mercke 
Ethidium Bromide Sigma 
Ethylenediamine tetra-acetic acid di-
sodium salt dehydrate (EDTA) 
Saarchem, Mercke 
Glycerol Saarchem, Mercke 
Hydrochloric acid Saarchem, Mercke 
Kanamycin Sulphate Roche 
Molecular grade agarose Bioline 
NuSieve GTG Agarose Cambrex 
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Sodium Chloride (NaCl) Saarchem, Mercke 
Tris[hydroxymethyl]aminomethane Roche 
Tryptone (Pancreatic digest of casein) Pronadisa 
Yeast extract Pronadisa 
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